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It has long been known that oxygen has the potential to 
be toxic to biologic systems and that this toxicity is 
not due to oxygen itself, 
oxygen radicals. One 
but due to the production of 
of these potentially toxic 
radicals, superoxide (02-) can be generated as a result 
of ionizing radiation, and if not adequately removed can 
proceed to cause cell damage. Superoxide dismutase 
(SOD) is one of the key enzymes involved in the defence 
against oxygen toxicity. 
by diethyldithiocarbamate 
chelator. 
SOD activity can be inhibited 
(DOC), a powerful copper 
If inhibition of SOD by DOC increases the lifetime and 
effectiveness of radiation induced o2-, it follows that 
the potential exists for DOC to enhance the effect of 
radiation. DOC is however also a thiol compound, and 
thus may act as a radioprotector by modifying tissue 
oxygenation status or by free radical scavenging. 
This study has concerned itself primarily with the 
inhibition of superoxide dismutase by 
diethyldi thiocarbamate in order to sensitize tumours to 
ionizing radiation. The use of DOC as an inhibitor 
of SOD has however meant that any sensitization resulting 
from SOD inhibition could be masked by a radioprotective 
effect by DOC. 
Abstract xv 
The inhibition of SOD by DDC was confirmed in a murine 
rhabdomyosarcoma, and it was shown that this inhibition 
can be maintained for up to twenty-four hours after DDC 
administration. It was hypothesised that there was a 
potential for the radioprotective effect of DDC to be 
overcome, if the levels of DDC were low enough at the 
time of irradiation. Indeed, if DDC was removed from 
the growth medium of B16 mouse melanoma cells in culture 
prior to irradiation, a significant sensitization was 
demonstrated. 
It was shown that DDC could act as both a radiosensitizer 
and as a radioprotector in the same experiment. The 
dominant action of DDC was found to be dependent on the 
time allowed between DDC administration and irradiation. 
If this time was approximately 4 hours, it was possible 
to show a radiosensi ti zing effect by means of a tumour 
growth delay assay. 
This time modulation effect of DOC was shown in larger 
tumours, rather than smaller tumours, which could 
indicate that tumour oxygenation is an important 
criterion in determining the response to radiation of DOC 
treated cells. 
It was shown that B16 mouse melanoma cells exposed to 
43°C after DDC pretreatment were sensitized to thermal 
damage. 
xvi Abstract 
This work suggests that some caution should be exercised 
when DDC is put forward as either a radiosensitizer or a 
radioprotector in the clinic, but that DDC may have 
potential as a thermosensitizer. 
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Chapter 1 
The toxicity of oxygen 
This section aims at providing an introduction to oxygen 
toxicity, 
radicals. 
the chemistry of oxygen and superoxide 
Some historical perspectives on the origins 
of oxygen toxicity and the evolution of protective 
mechanisms are included since the enzyme being studied in 
this thesis, superoxide dismutase, is thought to have 
arisen early in evolution as a protective mechanism 
against oxygen toxicity. 
Evolution of our solar system 
This has been very succinctly described by Dickerson 
( 1978) It is thought that the sun and planets of our 
solar system were formed from a revolving cloud of gas, 
dust particles and debris. Due to rotational and 
gravitational energy, the sun coalesced at the centre of 
this cloud. Local inhomogeneities at varying distances 
from the centre became aggregation points for the 
formation of the planets. The larger planets, Jupiter, 
Saturn, Uranus and Neptune probably represent a fair 
approximation of the composition of this original cloud, 
since their constituent elements are close to that of the 
universe at large. (They are composed mainly of 
hydrogen, helium, methane, ammonia and water). The 
small inner planets Mercury, Venus, Earth and Mars are 
richer in the heavier elements and poorer in the volatile 
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gases which could escape the weak gravitational pull of 
these planets. A combination of low gravity and high 
temperature led to a loss of most of the earth's volatile 
constituents soon after the planet coalesced. 
The relative abundance of oxygen was greatly increased, 
because it was locked into the non-volatile minerals. 
The original surface may have been too hot for water to 
remain liquid, but as soon as the temperature dropped 
below the boiling point, water released from the interior 
by outgassing processes such as volcanism would have 
condensed to form the original oceans. This would give 
rise to a secondary atmosphere composed of water vapour, 
methane, carbon dioxide, ammonia and hydrogen sulphide. 
The early atmosphere 
This atmosphere the character of which was reducing 
rather than oxidising, is probably where life arose. 
Oparin ( 1936) and Haldane ( 1954) first proposed that a 
reducing atmosphere (with no free oxygen) was a 
requirement for the evolution of life from non-living 
organic matter. Urey (1952) and Miller (1953) conducted 
laboratory experiments where they demonstrated that spark 
discharges (e.g. lightning) in aqueous mixtures of 
hydrogen, methane and ammonia gave rise to aldehydes, 
carboxylic acids, amino acids and strings of amino acids. 
From this is postulated the development of primitive 
protein and nucleic acid chains from the polymerisation 
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of these organic compounds, which eventually formed 
droplets and a membrane with an internal environment. 
The final stage would be the development of some type of 
reproductive machinery to ensure that daughter cells had 
all the chemical and metabolic capabilities of the 
parents. 
The first living organisms 
Some of the first living organisms, similar to green and 
purple sulphur bacteria, were able to produce energy rich 
molecules by photosynthesis using H2 s as a source of 
hydrogen atoms : 
light energy 
12H2S + 6C02 > Glucose (C6H12o6 ) + 12S + 6H2o 
Later 
plants 
the predecessors of blue-green algae and higher 
mastered the technique of photosynthesis using 
water as a source of hydrogen atoms 
light energy 
12H2o + 6C02 > Glucose (C6H12o6 ) + 602 + 6H20 
This process released oxygen into the early atmosphere, 
and transformed it into the one in which all subsequent 
life developed. 
With the evolution of photosynthetic cells that produced 
oxygen, the earth's atmosphere slowly began to change. 
As a result of photosynthesis, the concentration of 
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oxygen in the earth's atmosphere rose to 1 percent about 
600 - 1000 million years ago and to about 10% some 100 
million years ago. The present concentration of 21% has 
been created and is maintained by photosynthesis. The 
accumulation of oxygen in the air made possible the 
evolution of organisms that produce most of their 
chemical energy by cellular respiration. 
content of the atmosphere rose, it also 
As the oxygen 
changed the 
atmosphere from a reducing to an oxidising environment. 
Living matter was thus exposed to oxygen toxicity, that 
is , oxidations which were harmful or perhaps even lethal 
to the cells. 
The evolution of protective mechanisms 
There was considerable evolutionary pressure to develop 
protective mechanisms against oxygen toxicity or to 
retreat to environments that oxygen did not penetrate. 
Anaerobic organisms comprise a wide range of organisms 
with varying oxygen tolerance. For 'strict' anaerobes, 
for example Treponema denticola and several Clostridia, 
oxygen exposure is lethal, whereas moderate anaerobes 
such as faecal bacteria can survive some oxygen exposure 
(Halliwell & Gutteridge, 1985). 
The damaging effects of oxygen on strict anaerobes 
appears to be due to the oxidation of essential cellular 
components. Some enzymes in anaerobes are also 
inactivated by oxygen, for example the nitrogenase 
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enzyme, which catalyses the reduction of nitrogen to 
ammonia in Clostridium pasteurianum, is inactivated due 
to the oxidation of essential components in its active 
site. This enzyme is essential for the survival of the 
organism in environments poor in nitrogen compounds 
(Halliwell & Gutteridge, 1985). 
The efficient use of oxygen in aerobic organisms paved 
the way for the development of more complex multicellular 
organisms. However oxygen is dangerous and often lethal 
in high concentrations, and thus a selective pressure 
existed which favoured the proliferation of cells which 
had developed mechanisms to cope with the damaging 
effects of oxygen. 
Why oxygen is toxic to living organisms 
Before considering these mechanisms, it is pertinent to 
examine why oxygen is toxic to living organisms. 
The history of early biological and medical research into 
oxygen toxicity has been excellently reviewed by Gilbert 
(1981). 
Soon after the discovery of oxygen by Priestley in the 
1770s, it was recognised that oxygen might have 
therapeutic value, such as for the treatment of 
"asphixias by suffocation", but also that pure oxygen 
could be toxic 
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"If the atmospheric air were perfectly pure, the 
life of animals breathing it would be much more 
energetic, better and pleasant in many ways, but at 
the same time it might be proportionally shortened, 
and being rapidly consumed by such active air, they 
might only live one quarter of the time that they 
live in the ordinary air of the atmosphere, impure 
though it may be." (Macquer, 1777) 
The first report of oxygen toxicity was given in 1777 by 
Scheele : 
"Plants [peas], however will not grow noticeably in 
pure fire-air [oxygen]." 
Lavoisier ( 1782/83) autopsied guinea pigs that had died 
in oxygen, and found that : 
"all of them appeared to have died of a burning 
fever and of inflammatory sickness. Upon 
inspection, the flesh was very red, the heart was 
livid . . . the 1 ung was very flaccid . . . Heal thy air 
is therefore composed of a good proportion between 
vital air [oxygen] and atmospheric moffete 
[nitrogen] when there is an excess of vital air 
[oxygen], the animal undergoes a severe illness, 
when it is lacking, death is almost instantaneous." 
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Perhaps the earliest biochemical suggestion made to 
explain oxygen toxicity was that oxygen inhibits cellular 
enzymes (op cit, Halliwell & Gutteridge, 1985). 
A good example of this is photosynthesis. During 
photosynthesis, illuminated green plants fix co 2 into 
glucose in the Calvin cycle, a complex metabolic pathway 
where ribulose biphosphate carboxylase combines co 2 with 
a 5-carbon sugar (ribulose 1,5-biphosphate) to produce 2 
molecules of phosphoglyceric acid. Oxygen inhibits this 
reaction by competing with co2 , resulting in less CO 2 
fixation and less plant growth at elevated oxygen 
concentrations. 
In general however, the rates of enzyme inactivation by 
oxygen in anaerobic cells are too slow and too limited in 
extent to account for the rate at which toxic effects 
develop, and many enzymes are unaffected by oxygen at 
all. This led Gershman et al. ( 1954) to propose that 
most of the damaging effects of oxygen could be 
attributed to the formation of oxygen radicals. 
In order to understand why oxygen is toxic to living 
organisms, we must first examine the basic chemistry of 
oxygen, and of free radicals. 
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Notes on the chemistry of oxygen 
In covalent bonding, where electrons are shared between 
atoms, the atomic orbitals are transformed to molecular 
orbitals. 
There are 2 types of molecular orbitals 
* Bonding molecular orbitals e.g. o1s, which are 
more stable than the atomic orbitals. 
* Anti-bonding molecular orbitals e.g. o*1s, which 
are less stable than the atomic orbitals. 
The bonding molecular orbitals are more stable than the 
atomic orbitals. 
hydrogen and helium. 
To illustrate this let us examine 
The bonding molecular orbitals are the most stable, and 
of lowest energy. They are even more stable than the 
atomic orbitals. For example, hydrogen atoms each have a 
single electron in the 1 s atomic orbital. ( 1 s 1 ) When 
hydrogen atoms combine to form the hydrogen molecule, the 
two electrons in the atomic 1 s orbitals enter the o1 s 
bonding molecular orbital, each electron having opposite 
spin ( in accordance with Pauli's principle) . 
is more stable than isolated H atoms. 
Hence H2 
For the sake of argument, let us examine what would 
happen should helium atoms combine to form He2 : helium 
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atoms contain 2 electrons in the 1s atomic orbital. 
( 1 s 2 ) Should helium atoms combine, 2 electrons would 
share the o1s bonding molecular orbital, and the other 2 
would share the o*1s anti-bonding molecular orbital. As 
mentioned earlier, this state is less stable than the 
atomic state, thus He2 does not form. 
Combination of p-type atomic orbitals can produce 2 types 
of molecular orbitals by overlapping in different ways, 
and are known as o and rr orbitals. Hence for one of 
the 2px orbitals combining with another such orbital, 
there will be two bonding molecular orbitals o2px and 
rr2px, and 2 anti-bonding molecular orbitals (o*2px and 
rr*2px). The energy would increase in the order of 
Forms of molecular oxygen 
Oxygen has the configuration of 1s2 2s2 2p4 or 
1s 2s 2p 
0 
If the atoms combine to form a diatomic molecule (02 ), 
the four 1 s electrons ( 2 from each atom) fully occupy 
both o1s bonding and o*1s anti-bonding molecular 
orbitals, so there is no net bonding. Similarly the 
four 2s electrons occupy the o2s bonding and o*2s anti-
bonding molecular orbitals, and again no net bond 
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results. Of the eight electrons remaining, six fill 
the o2px, n2py and n2p
2 
bonding molecular orbitals, and 
the remaining two must occupy the next highest molecular 
orbital in terms of energy. There are 2 such orbitals 
of equal energy namely the n*2p and n*2p anti-bonding y z 
molecular orbitals. By Hund's Rule, each must receive 
one electron. Since the presence of electrons in anti-
bonding orbitals energetically cancels out one of the n2p 
bonding orbitals, the two oxygen atoms are effectively 
joined by a double 0=0 bond. 
Ground state o2 
o1s o*1s o2s o*2s o2p n2p n*2p o*2p 
B B B B B EE] mo 
If oxygen attempts to oxidise another atom or molecule by 
accepting a pair of electrons from it, both of these 
electrons must be of anti-parallel spin so as to fit in 
the vacant spaces of the n*2p orbital. A pair of 
electrons in an atomic or molecular orbital would not 
meet this criterion however, as they would both have 
opposite spin in accordance with Pauli's principle. 
This imposes a restriction on electron transfer which 
makes oxygen accept its electrons one at a time and also 
means that oxygen reacts sluggishly with non-radicals. 
This spin restriction prevents the spontaneous combustion 
of many organic compounds in the presence of oxygen. 
The toxicity of oxygen 7 7 
Singlet oxygen 
With an input of energy, the o2 molecule can be converted 
to singlet oxygen, which is more reactive. 
Singlet oxygen can exist as singlet oxygen 16g o2 , 22.4 
kcal above the ground state 
o1s o*1s o2s o*2s o2p n2p n*2p o*2p 
BBB BB EB EDD 
or as singlet oxygen 1Eg+ o2 , 37.5 kcal above the ground 
state. 
o1s o*1s o2s o*2s o2p n2p n*2p o*2p 
BBB BB EB DD 
In both forms of singlet oxygen, the spin restriction is 
removed and the oxidising ability is greatly increased 
(Halliwell & Gutteridge, 1985). 
The superoxide radical 
If a single electron is added to ground state o2 , it must 
enter one of the n*2p anti-bonding orbitals. This 
weakens the oxygen-oxygen bond, and results in only 11 
covalent bonds between the oxygen atoms in superoxide 
Addition of another electron forms the peroxide 
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ion which is not a radical and weakens the 0-0 
bond to a single covalent bond. 
The superoxide radical, o2- can be designated 
o1s o*1s o2s o*2s o2p n:2p n:*2p o*2p 
B B B B B EB EEJD 
and the peroxide ion o2
2 -
o1s o*1s o2s o*2s o2p n:2p n:*2p o*2p 
BBB BB EB EBO 
As can be seen, superoxide has only one unpaired 
electron, and one could argue that it is therefore less 
of a radical than oxygen in the ground state. 
The biology of superoxide radicals 
A free radical may be defined as any species capable of 
independent existence that contains one or more unpaired 
electrons (Halliwell & Gutteridge, 1985). The presence 
of unpaired electrons causes the species to be attracted 
slightly to a magnetic field and sometimes makes the 
species highly reactive. 
Radicals can be formed when a covalent bond is broken, 
and one electron from the shared electron pair remains 
with each atom (hemolytic fission). The energy required 
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to break covalent bonds can be obtained from, for example 
electromagnetic radiation, such as X or gamma rays. 
Chemistry of superoxide 
One of the reactions of superoxide in aqueous solution is 
to act as a base, that is a proton acceptor. 
When o
2 
- accepts a proton, it forms the hydroperoxyl 
radical ( H02 • ) . H02 • can dissociate again and release 
H+ ions, i.e. act as an acid. 
ions are mixed, an equilibrium is set up : 
(--) 
The pH at which the acid ( H02 ·) and base ( o2 - ) are in 
equal concentrations (i.e .. the pKa) is 4.8. As the pH 
of most body tissues is in the range 6. 4 to 7. 5, the 
ratio [02-] /[H02 °] will be very large.
1 e.g .. 100:1 at 
pH 6. 8. Hence any o2 - generated will remain almost 
entirely in this form, rather than being protonated. 
However, superoxide dissolved in aqueous solution 
disappears very rapidly. The reason for its' 
disappearance is the dismutation reaction: 
Henderson-Hasselbalch equation 
log10 ([base]/[acid]) 
pH = pKa + 
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1 0 3 -1 -1 The rate constant for this reaction is on y . M .s , 
whereas the reaction: 
+ 
--> 
Hence dismutation is most rapid at acid pHs and will 
become slower as the pH rises. 
o2 - can also act as a reducing agent (donor of 
electrons). For example it can reduce cytochrome c, 
wherein ferric iron is reduced to ferrous iron. 
o2 is also a weak oxidising agent ( electron acceptor) . 
For example o2 oxidises ascorbic acid (k2 = 2. 7 X 1 o
5 
M-1 . s-1) 
ascorbate + o2- + 2H+ --> H2o2 + ascorbate radical 
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Radicals generate radicals 
The reaction of a free radical with a non radical species 
produces a different free radical, which may or may not 
be less reactive than the original radical. 
The reactions of superoxide will therefore often produce 
other radicals or species such as H2o2 , HOCl, o3 or 
singlet oxygen which although they are not radicals 
themselves, can produce free radicals. 
Superoxide is produced constantly at low levels in cells 
by a number of mechanisms. 
* It can be produced by normal chemical reactions 
within the cell. 
* It can be produced as a by-product of a leaky 




Xanthine oxidase produces o2 during the oxidation 
of hypoxanthine. 
o2 production plays an essential role in 
phagocytosis (Baboir, 1978). 
Chemotaxis, lymphocyte regulation, fibrosis and 
proliferation all involve low levels of o2 
production (Halliwell, 1990). 
Site specific damage 
The expression of o2- toxicity is through its ability to 
reduce transition metal compounds (for example copper and 
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iron compounds), which are subsequently reoxidised by 
H2o2 yielding deleterious entities such as OH (Czapski & 
Goldstein, 1987). 
This proposed mechanism has given rise to much 
controversy due to the very high concentrations of OH. 
scavengers necessary to protect cells from 0 2- mediated 
toxicity (Czapski, 1984). It has therefore been 
suggested that the reactions of o2 - and metal compounds 
proceed with the metal compound bound to a biological 
target ( Goldstein & Czapski, 1986a) . This allows the 
formation of OH in the vicinity of the target, making 
effective OH scavenging difficult. This results in 
what is known as the site specific mechanism. 
1984) . 
(Czapski, 
Radicals produced within the cell may then cause damage 




reaction with critical -SH groups on membrane ion 
pumps. 
DNA fragmentation by strand breakages. 
lipid peroxidation can increase the 'leakiness' of 
membranes, allowing ions such as ca2+ to cross the 
membrane. An increased intracellular ca2+ 
concentration can activate proteases and nucleases 
and this can lead to the inactivation of many 
intracellular enzymes and also to DNA damage 
(Halliwell, 1990). 
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The role of iron and copper 
Superoxide can reduce iron, and together with hydrogen 
peroxide can form the highly reactive hydroxyl radical. 
This mechanism is essentially an iron catalysed 
Haber-Weiss reaction (Haber & Weiss, 1934) as shown 
below. 
Fe3+ + o 2 <--> perferryl <--> 





--) OH-+ Fe3 + + OH 
The Fe(IV) ferryl compound can be either very stable or 
unstable, depending on what binds to it. The stability 
of ferryl can therefore limit OH production in the cell 
(Halliwell, 1990). 
Iron taken up in the gut enters the blood as the plasma 
protein transferrin, which functions as a carrier 
molecule. Transferrin binds to iron extremely tightly, 
making it unavailable to o 2- attack. Transferrin under 
normal conditions is only about 30% saturated with iron, 
so the amount of extracellular iron is extremely low. 
Transferrin binds to receptors on the cell surface and is 
internalised, entering the cytoplasm in a vacuole. The 
contents of this vacuole are then acidified to facilitate 
the release of iron into the cell. This protein-bound 
iron can then be used in the synthesis of other iron-
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containing proteins. Any iron not required by the cell 
is stored in the protein ferritin, which appears to 
prevent an excessive intracellular buildup of non-
protein-bound iron. However a small pool of 
intracellular non-protein-bound iron exists and could be 









concentrations, where all iron is protein-bound, attached 
to transferrin and unable to be catalysed by free radical 
reactions. It is the function of the intracellular 
antioxidant enzymes to prevent o2 - coming into contact 
with the free iron pool (Halliwell, 1990). 
Iron overload can lead to, for example, haemachromatosis, 
many of the consequences of which can be explained in 
terms of free radical reactions. There is no obvious 
physiological mechanism for disposing of excess iron. In 
conditions of excessive intake, for example where acidic 
beer is brewed or food cooked in iron pots (as in some 
regions of Africa) or in overdoses of iron tablets, iron 
overload results, with resultant saturation of 
transferrin, and an increased amount of free iron in the 
plasma (McGilvery & Goldstein, 1983). 
The reaction of o2- with copper ions can also undergo a 
Haber-Weiss reaction and produce OH
0
• 
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--> Cu+ 0 + 2 
+ OH 
Copper ions bound to biological targets or chelators can 
still act as catalysts for the Haber-Weiss reaction. 
Biol-cu2 + + 02 --) Biol-Cu+ + 02 
Biol-Cu + H202 (Biol-cu
2 + 
... OH.) OH + --> + 
This modified mechanism describes the 'site specific 
mechanism' (Goldstein & Czapski, 1986a). 
Copper and iron can also catalyse the dismutation of 0 2-
by the following reaction. 
cu2+ or Fe3+ + o2 --) cu+ or Fe
2+ 
cu+ or Fe2+ + + 2H+ --> cu2+ or Fe 3+ + 
(Fridovich, 1981). 
In this sense copper or iron ions may act either as 
damaging or protective compounds depending on the 
relative contribution of the metal catalysed Haber-Weiss 
reaction and the dismutation reaction respectively. 
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A history of superoxide dismutase 
As discussed earlier, superoxide, one of the products of 
the biological reduction of molecular oxygen, can proceed 
to produce other radicals which can be extremely toxic to 
the cell. Even though superoxide has only a short 
lifetime, the production of this free radical has 
necessitated the evolution of enzymes whose function it 
is to catalyse the very reaction which occurs rapidly 
without enzyme catalysis. 
The dismutation of superoxide, 
is catalysed by superoxide dismutase (SOD). 
SOD was first isolated by Mann & Keilen in 1938, 
crystalised by Mohammed and Greenberg in 1953 and 
extensively studied by Markowitz et al. (1959) and 
Carrico & Deutsch ( 1969) as a copper containing protein 
of unknown function ( op cit McCord & Fridovich, 1977). 
An excellent review of the events that led to the 
discovery of SOD is presented in McCord & Fridovich' s 
1977 paper, and is discussed below. 
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First steps on the road to SOD discovery - sulphite 
oxidation 
In 1941 Handler et al. described a sarcosine oxidase 
activity in rat liver homogenates. They found that 
sarcosine (N-methyl-glycine) was oxidised to formaldehyde 
and glycine. (Fig 2.1). 
N-methylglycine (sarcosine) 
2 H N+ CH 3 - 2 COO <J_> 2 H - [ -H 
glycine formaldehyde 
Figure 2. 1. Sarcosine is oxidised to formaldehyde and glycine by a compound 
found in rat liver homogenates. 
Heimberg et al. ( 1953), as part of their studies on 
sarcosine oxidase were examining the use of sulphonic 
acid analogues of sarcosine as possible competitive 
inhibitors. The sulphonic acids were themselves 
oxidised by the liver preparations and one of the 
products was sulphate. The sulphonic acids were 
substrates because they dissociated to sulphite which was 
rapidly oxidised to sulphate in the presence of the liver 
homogenates. 
Thus the existence of an enzyme catalysing the oxidation 
of inorganic sulphite was demonstrated. The enzyme 
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activity was found to be localised in liver mitochondria 
(Fridovich & Handler, 1954). 
Hypoxanthine found to facilitate sulphite oxidation 
It was found that dialysis of this enzyme caused a loss 
of activity, which could be restored by addition of a 
heat stable, dialysable component 





substance, which behaved like a classical enzyme cofactor 
was found to be hypoxanthine. (Fig. 2.2). 
Figure 2.2. Hypoxanthine 
The facilitation of sulphite oxidation by hypoxanthine 
led to the suspicion that the enzyme xanthine oxidase was 
involved. This enzyme catalysed its substrates 
hypoxanthine and xanthine to urate. (Fig. 2.3). 
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Figure 2.3. Xanthine oxidase catalyses the conversion of hypoxanthine and 
xanthine to urate. 
Free radical chain oxidation of sulphite 
23 
The aerobic oxidation of sulphite is complicated by the 
tendency of sulphite to undergo a free radical chain 
oxidation. This was shown by an effect of cytochrome c. 
The sulphite slowly reduced cytochrome c which caused the 
aerobic oxidation of sulphite; however the relative rates 
of these reactions were such that thousands of sulphite 
ions were oxidised per cytochrome c reduced. It was 
apparent that the oxidation of one sulphite by cytochrome 
c generated a species, probably a radical, which then 
caused the aerobic oxidation of many sulphite ions. 
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Xanthine oxidase initiates the free radical chain 
oxidation of sulphite 
Xanthine oxidase, at very low concentrations was found to 
catalyse the oxidation of sulphite in the presence of its 
purine substrates, hypoxanthine and xanthine. In the 
absence of these substrates, the enzyme had no effect on 
sulphite oxidation (Fridovich & Handler, 1958a). 
Numerous other oxidases were found unable to initiate 
sulphite oxidation, and thus one had to suppose that the 
xanthine oxidase reaction produced some special product 
which was reactive enough to start the sulphite chain 
reaction. Since uric acid and H2o2 were unable to do 
this, an intermediate of oxygen reduction was suspected 
(Fridovich & Handler, 1958b). 
This was confirmed by Fridovich and Handler in 1961, who 
demonstrated that o2 - produced by platinum electrodes in 
solution initiated sulphite oxidation. They argued that 
the initiation of sulphite oxidation by xanthine oxidase 
was due to the generation of oxygen radicals during the 
course of its catalytic action. 
A mystery inhibitor of cytochrome c reduction by 
xanthine oxidase 
At this time, the literature concerning the reduction of 
cytochrome C by xanthine oxidase was confusing. 
Cytochrome c was reported to be both a good and a poor 
electron acceptor. It was found that xanthine oxidase 
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reduced some samples of cytochrome c, while others were 
hardly reduced at all. Furthermore, those samples found 
not reducible by xanthine oxidase were found to contain a 
potent heat-labile and non-dialysable inhibitor of 
cytochrome c reduction. This was a very specific 
inhibitor, since it prevented the reduction of cytochrome 
c by xanthine oxidase acting on xanthine, but had no 
effect on the rate of reduction of oxygen (Fridovich & 
Handler, 1958b). 
Was it myoglobin that bound to the active site? 
Since the globin of myoglobin was a frequent contaminant 
of the horse heart cytochrome c being used, myoglobin and 
the corresponding globin were prepared and were found to 
be powerful competitive inhibitors of cytochrome c 
reduction by xanthine oxidase (Fridovich, 1962). 
Furthermore, enzymatic scavengers of H2o2 did not prevent 
the reduction of cytochrome c by xanthine oxidase. 
It appeared most probable that o2 generated on the 
enzyme and bound to it was responsible for the reduction 
of cytochrome c by xanthine oxidase, and that myoglobin 
or its globin had inhibited this by binding to this o2 
site, thereby preventing access by cytochrome c 
(Fridovich & Handler, 1962). 
It was later observed that when methylene blue was added 
to an aerobic xanthine oxidase - xanthine - cytochrome c 
reaction, the dye-mediated cytochrome c reduction yielded 
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different kinetic constants, but still showed classical 
hyperbolic saturation despite the fact that the enzyme 
reduced dye was thought to transfer electrons to 
cytochrome c 
concentrations, 
in free solution. At low cytochrome c 
the reduced dye, unable to find 
cytochrome c to accept the electrons, could simply 
autooxidise (McCord & Fridovich, 1968). McCord argued 
that oxygen could carry electrons in a manner completely 
analogous to methylene blue, through free solution. At 
low cytochrome c concentrations, superoxide could largely 
autooxidise via its dismutation reaction and at high 
cytochrome c concentrations, the complete scavenging of 
o2- by the cytochrome c would be approached. 
McCord & Fridovich (1968) to predict that 
This led 
superoxide 
production is first order in xanthine oxidase, while its 
disappearance via dismutation in free solution is second 
order in the radical. 
Possible presence of a superoxide interceptor 
This understanding forced a re-assessment of how the 
various protein preparations inhibited the phenomenon. 
No longer could a binding mechanism be invoked, but the 
inhibitory proteins had to intercept superoxide in free 
solution, preventing it from reaching cytochrome c. The 
only explicable means of achieving this was a catalytic 
decomposition of the radical - a superoxide dismutase. 
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Superoxide dismutase isolated 
McCord then isolated superoxide dismutase (SOD) from 
bovine erythrocytes on the basis of its enzymic activity. 
Once it was pure, the identity between this blue-green 
copper containing SOD and the previously described bovine 
hemocuprein (Mann & Keilen, 1938) and human 
erythrocuprein (Markowitz et al., 1959) was apparent 
(McCord & Fridovich, 1969a). 
It was later found that the preparations of myoglobin 
then used contained a small amount (< 1%) of SOD, which 
by catalytically scavenging o2-, prevented all the 
reactions dependent on this radical, without inhibiting 
the enzymatic turnover of xanthine oxidase (McCord & 
Fridovich, 1977). 
Evolution of SOD 
Superoxide dismutases are thought to have arisen early in 
evolution at the time when aerobic life was developing 
( Steffens et al., 1983), as a defence mechanism against 
oxygen toxicity. Respiring organisms, 
bacteria (Yost & Fridovich, 1973), fungi 
including 
(Misra & 
Fridovich, 1972b), algae (Misra & Keele, 1975), plants 
(Asada et al• I 1973) J molluscs and arthropods 
(Tegelstrom, 1975), fish (Bannister et al., 1976), birds 
(Weisiger & Fridovich, 1973) and mammals (McCord & 
Fridovich, 1969b), all contain superoxide dismutases. 
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Oxygen sensitive obligate anaerobes do not contain the 
enzyme (McCord et al., 1971). 
It is thought that superoxide dismutases evolved along 
two separate lines into three groups with different 
catalytic ions in their active sites (Fridovich, 1981). 
There are superoxide dismutases based on iron ( FeSOD) , 
manganese (MnSOD) and copper plus zinc (CuZnSOD). 
MnSOD and FeSOD appear to be related by extensive amino 
acid homology, whereas CuZnSOD represents an 
independently evolved group (Fridovich, 1981). All of 
these enzymes have comparable catalytic efficiency in 
catalysing the dismutation of o2-. 
Copper zinc superoxide dismutase 
CuZnSODs are cytoplasmic enzymes, predominantly found in 
eukaryotes. An exception is the symbiotic bacterium 
Photobacterium leiognathi. Since its host, the pony 
fish, has evolved a special gland to house this 
photobacterium, the symbiosis is one of long standing. 
It is speculated that the bacterium obtained the CuZnSOD 
,by gene transfer from the host fish (Puget & Michelson, 
1974). 
Each molecule of CuZnSOD is a dimer of identical subunits 
that contain approximately 153 amino acids, a copper and 
a zinc ion (Getzoff et al., 1989) The Cu ion, essential 
in the catalysis of the dismutation reaction is 
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cyclically oxidised and reduced during successive 
encounters with o2-, as shown below 
S0D-cu2+ + o2 ~-> 
SOD-Cu+ + o2 + 2H+ 
(Fridovich, 1979). 
SOD-cu++ 02 
2+ ~-> SOD-Cu + H2o2 
Both reactions have rate constants of 1.6 X 109 M- 1 . s- 1 
and both rates are probably limited by the availability 
of substrate (Klug et al., 1972) . This availability of 
substrate is increased as most of the surface of the 
molecule is negatively charged except for channels of 
positive charge that direct o2 - to the active site (Cudd 
& Fridovich, 1982). 
The structure of bovine CuZnSOD has been elucidated by 
X-ray crystallography to a resolution of 2ft. (Tainer et 
al• I 1982) • Each subunit is composed of a set of eight 
antiparallel a-strands forming a flattened barrel, plus 
two external loops forming the active site. (Fig 2.4) 
The two subunits are joined by noncovalent, predominantly 
hydrophobic interactions between the a-barrels such that 
the active sites are on opposite sides of the dimer. 
30 Chapter 2 
Figure 2.4 A computer graphic analysis of the human SOD dimer showing the 
B-strands and the active site (Cu ion - yellow sphere; Zn ion - blue sphere). 
Photographed from the cover of Proteins 5 No.4 (1989). 
The copper ion is held at the active site by interaction 
with nitrogens in imidazole ring structures of four 
histidine residues. It is situated on the surface of 
the barrel, at the base of a channel formed by the two 
external loops ( Tainer et al. , 1982) . The one loop 
contains most of the residues important in the 
electrostatic guidance of o2 to the Cu ion (Getzoff et 
al• I 1983) • 
The second loop, which binds to zn2+, contributes to the 
high stability of the enzyme (Forman & Fridovich, 1973). 
CuZnSOD is an unusually stable enzyme which can remain 
active in 8M urea (Malinowski & Fridovich, 1979) and 4% 
sodium dodecyl sulphate (Forman & Fridovich, 1973) and 
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has a conformational melting temperature of 96°C (Lepcock 
et al., 1985 ; Roe et al., 1988). 
Iron and manganese superoxide dismutase 
FeSOD has been found only in prokaryotes and algae, 
whereas MnSOD is found in both prokaryotes and 
eukaryotes. In eukaryotic organisms, MnSOD is localised 
in the mitochondrial matrix supporting speculations 
concerning the symbiotic origin of these organelles 
(Fridovich, 1981). It is thought that mitochondria 
evolved as a symbiosis between a primitive eukaryote 
(with CuZnSOD) and a prokaryote (with MnSOD) that 
eventually became 
cytoplasm. 
incorporated into the eukaryotic 
Amino acid sequence analysis has confirmed a close 
evolutionary relationship between MnSOD and FeSOD 
(Steinman, 1978). As with CuZnSOD, the enzymes operate 
by a redox cycle in which the active site metal is 
reduced by one o2 - and then reoxidised by another o2- as 
shown below where Men represents a heavy metal cation. 
--) 
(Fridovich, 1981). 
Men- 1 + 0 
2 
Iron and manganese oscillate between 
trivalent and divalent states, and copper oscillates 
between divalent 
catalytic cycle. 
and univalent states during the 
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Biological role of superoxide dismutase and the 
antioxidant enzymes 
It has been argued that SOD is not unique in its function 
to catalyse o2 - dismutation (Fee, 1981) and that many 
copper compounds have similar catalytic efficiencies to 
that of the native SOD. Indeed, many copper compounds 
have been shown to have SOD activity in vitro (Czapski & 
Goldstein, 1987). 
A possible explanation for the inability of these copper 
compounds to catalyse o2 dismutation in vitro is that 
they can form ternary complexes with biological 
macromolecules such as DNA. It has been shown that 
ternary complexes of DNA and some copper complexes react 
extremely slowly with o2 - (Goldstein & Czapski, 1986b). 
Superoxide generated enzymatically, photochemically or 
radiochemically has been shown to peroxidise lipids 
(Petkau & Chelack, 1974), cleave DNA (Lown & Weir, 1978), 
inactivate enzymes (Lin et al• I 1978) and lyse 
erythrocytes (Stone et al., 1978). 
Superoxide and H2o2 individually may not be as reactive 
as other free radicals, but they can 'conspire' to 
produce OH. by the iron catalysed Haber-Weiss reaction as 
shown in Chapter 1 and thus cause widespread biological 
damage (Fridovich, 1981), and this would certainly 
explain the need for a comprehensive enzymatic defence 
mechanism against such events. 
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Figure 2. 5 summarises the enzymatic defense mechanisms 
against radiation induced oxygen toxicity. 
Biological 
damage 
Figure 2.5 The enzymatic defense mechanisms against radiation induced oxygen 
toxicity. SOD - superoxide dismutase; CAT - catalase; GPx - glutathione 
peroxidase; GR - glutathione reductase; GSH reduced glutathione; GSSG -
oxidised glutathione; R - biologically important molecule; e-aq - hydrated 
electron. 
Klug et al. (1972) irradiated a solution of sodium 
formate, EDTA, and cuso4 with pulses of 5 MeV electrons 
of 1~ µseconds duration and then measured the absorbance 
at 245 nm, and found that in the absence of SOD, o2 can 
remain for about 20 seconds, whereas it is catalysed to 
oxygen and H2o2 within 2 msec in the presence of SOD. 
34 Chapter 2 
Hydrogen peroxide can be removed by catalysis by either 
catalase (CAT), which catalyses the reaction: 
CAT 
2H2o2 ~~> 2H20 + 0 2 
or glutathione peroxidase (GPx), which catalyses the 
reaction : 
GPx 
The catalase reaction proceeds as follows 
~~~> compound 1 
Compound 1 is thought to be either CAT-Fe (III) -HOOH or 
CAT-Fe(V)=O. 
liver catalase 
The second order rate constants for rat 
are 1 .7 X 10 7 M- 1 .s- 1 and 2.6 X 10 7 
M- 1 .s- 1 respectively (Halliwell & Gutteridge, 1985). 
Glutathione peroxidase also catalyses the oxidation of 
GSH to GSSG at the expense of H2o2 . 
GPx 
Glutathione is a simple tripeptide (glutamic acid 
cysteine glycine) in its reduced form. In the 
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oxidised form (GSSG), two molecules of GSH join together 
as the -SH groups of cysteine are oxidised to form a 
disulphide bridge -s-s-. 
Gly Gly Gly 
I GPx I I 
Cys - SH + H202 > Cys - s - s - Cys + 2H20 
I I I 
Glu Glu Glu 
2 GSH GSSG 
The ratio of [GSH]/[GSSG] in normal cells is kept high, 
and this is done by glutathione reductase (GR) which 
catalyses the reduction of GSSG back to GSH in the 
reaction : 
GR 
GSSG + NADPH + H+ ~~~> 2 GSH + NADP+ 
This then is the major enzymatic antioxidant defense, as 
if these reactive species go unchecked they can proceed 
to cause lethal damage to the cell as explained in 
Chapter 1. 
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Diethyldithiocarbamate 
Diethyldithiocarbamate is the reduced form of disulfiram 
(tetraethylthiuram disulphide) or Antabuse. Disulfiram 
has been used for over 30 years in the treatment of 
chronic alcoholism. 
C2H5 s s C2H5 
\ II II I 





N - C - SH Diethyldithiocarbamate 
(DOC) I 
Diethyldithiocarbamate (DOC) has been used in the 
treatment of nickel carbonyl (Sunderman, 1979), arsenic 
and thallium poisoning, (Zemaitis & Greene, 1979) and in 
the treatment of Wilson's disease (hepatolenticular 
degeneration), a genetic disturbance of copper metabolism 
where biliary excretion of copper from the liver, and the 
formation of ceruloplasmin, the principal means of copper 
export from the liver, are below normal. This results 
in a buildup of copper in various organs and can result 
in development of liver cirrhosis and neurological 
degeneration. Treatment involves the administration of 
a chelating agent, usually penicillamine or 
Diethyldithiocarbamate 
diethyldithiocarbamate to remove 




DOC has also been suggested as an adjuvant to 
cis-platinum chemotherapy as it has been shown to limit 
kidney, gut and bone marrow toxicities in animal studies 
without limiting the anti tumour effect of cis-platinum 
(Bodenner et al., 1986; Dible et al., 1987). It has 
also been suggested as a 'rescue' therapy to combined 
cis-platinum and radiation (Douple & Richmond, 1982). 
It has been used 
(Parades et al., 
in humans at a dose of 600 mg/m2 
1988) but did not provide any 
protection from cis-platinum toxicity. 
DOC has also been shown to suppress ejaculation in dogs 
due to suppression of noradrenaline biosynthesis (Kimura 
et al. , 1979) . 
SOD inactivation by DDC 
As mentioned in Chapter 2, copper ions in CuZnSOD are 
essential in the catalysis of the dismutation reaction. 
DDC removes the copper from SOD and thus inactivates it 
(Heikkila et al., 1976). 
Heikkila & Cohen ( 1977) measured the content of SOD in 
brain, liver and blood of mice treated with DDC. (Table 
3.1) Tissues were removed 3 hours after i.p. injection 
of 1 .5 g/kg DDC and their SOD activity measured. 
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Table 3.1. Superoxide dismutase activities in brain, liver and blood of mice 
three hours after treatment with 1.5 g/kg DDC. (From Heikkila & Cohen, 1977). 
Tissue SOD (µg/g) ± SD 
Control DDC % Loss 
Brain 100 ± 6 52 ± 10 48% 
Liver 697 ± 80 200 ± 32 71% 
Blood 88 ± 12 12 ± 12 86% 
This dose of DDC, if uniformly distributed throughout the 
animal represents an average concentration of 9 X 10-3M. 
In contrast to the large decreases in SOD activity, liver 
and blood catalase measured 3 hours after 1. 5 g/kg DDC 
were 85 ± 5% (n=20) and 97 ± 7% (n=11) of their 
respective control values. It was concluded that the 
large decreases in SOD activity brought about by DDC in 
vivo was not the result of non-specific tissue damage. 
These investigators also measured the loss in SOD 
activity in mouse liver 3 hours after injection with 
various doses of DDC. 
is shown in Table 3.2. 
( Heikkila & Cohen, 1977) . This 
Table 3.2 SOD activity in mouse liver 3 hours after injection with DDC. (From 
Heikkila & Cohen, 1977). 
DDC dose Liver SOD % Loss 
(g/kg) (µg/g ± SD) 
0 632 ± 48 
0.5 368 ± 80 42% 
1. 0 200 ± 48 68% 
1. 5 168 ± 32 74% 
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In another experiment, male Swiss-Webster mice were 
injected i.p. with a solution of DDC in isotonic saline. 
Mice were injected with DDC at doses between 0.5 and 1.5 
g/kg. At various time periods the animals were 
sacrificed, tissues removed and their SOD content 
determined (Heikkila, 1984). It was shown that 1.5 g/kg 
DDC resulted in losses of SOD ranging from 50 - 90% in 
various tissues. It was argued that this treatment of 
mice clearly resulted in a loss of tissue SOD activity. 
However it was also stated that the mode of action of DOC 
is complex and most probably does more than just 
inactivate SOD. DOC is known to inactivate other copper 
containing enzymes, and furthermore DDC is a modestly 
good reducing agent as well as a free radical scavenger 
(Heikkila, 1984) . It was argued that any conclusions 
about SOD actions in vivo, based on DOC experiments 
should be drawn with extreme caution. 
Structural analogues of DDC 
FLA-57 is a structural analogue of DOC, and like DDC is a 
potent copper chelator and a commonly used inhibitor of 




C - SH FLA-57 
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SOD (1 mg/ml) and FLA-57 (10- 2M) were incubated alone and 
together at 37°C in water for 2 hours after which 10 µl 
aliquots were assayed for SOD activity (Heikkila & Cohen, 
1977). The inactivation in vitro of SOD by FLA-57 
appeared similar to that by DOC. 
completely reversed by incubation 
This inactivation was 
with CuSO 4 . The 
results were interpreted by these investigators as 
indicating that the -NCSSH grouping is an important 
structure for the inactivation of SOD. 
A number of other copper chelating compounds (both 
cuprous and cupric chelators) such as methimazole, 
penicillamine, propylthiouracil, phenylthiazolythiourea, 
pyridyldiphenyltriazine, cuprizone, bathocuprine and 
diethyldithiophosphate were tested as SOD inhibitors 
(Heikkila & Cohen, 1977). 
on SOD activity in vitro. 
These compounds had no effect 
Heikkila & Cohen (1977) suggested that these potent 
copper chelators fail to inhibit SOD in vitro as they 
cannot chelate protein bound copper which is in contrast 
to DOC and FLA-57. 
Interestingly, although exposure to penicillamine had no 
demonstrable effect in vitro, it has been shown to 
inhibit SOD activity in vivo (Albergoni et al., 1975). 
Penicillamine administration twice daily for 20 days at 
150 mg/kg caused relatively modest losses in SOD activity 
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compared to the large losses caused by a single injection 
of DOC. 
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Radiosensitization by DDC 
Increased radiation haemolysis 
Stone et al. (1978) showed that human erythrocytes were 
radiosensi ti zed by DDC. They argued that substantial 
amounts of haemolysis (the loss of integrity of the 
membrane, leading to the liberation of haemoglobin and 
other cellular macromolecules) could be produced by o2 
if the rate of o2 - production exceeded the rate of o2 
removal by SOD. In the absence of DDC, there was no 
haemolysis up to about 2 Gy, however when suspensions 
were incubated with 2. 4 mM DOC for 90 minutes prior to 
irradiation, complete haemolysis was demonstrated at 
Gy. This effect was still observed even when the DOC 
was added immediately or 1 hour after radiation. If DDC 
was washed out from the cells before irradiation, very 
little haemolysis was observed. They asserted that this 
meant that the concentration of DOC entering the 
erythrocyte was insufficient to inhibit SOD to a critical 
level or that a large concentration of DDC must be 
present at all times to maintain the inhibitory effects 
on SOD. 
Radiosensitization by DOC 
Modification of slope and shoulder of survival 
curve 
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Lin et al. (1979a) showed that DOC sensitized DON cells 
(an established cell line derived from the lung tissue of 
Chinese hamsters) to 2. 5 Gy gamma-irradiation. Cells 
were incubated with DOC for hour at 25°C prior to 
radiation. They showed that DOC enhanced the effect of 
radiation by a factor of 1.7 for cells exposed to 10- 4M 
DOC for 30 minutes prior to irradiation (Table 4.1). 
The enhancement appeared to be concentration dependent. 
Table 4. 1 Change in survival of DON cells after various concentrations of DDC 
or simultaneous treatment with DOC and 2.5 Gy of gamma radiation. (From Lin et 
a 1 . , 1979a). 
Radiation DDC Concentration 
Dose Control 10-SM 10-6M 10-7M 
~ 
0 survival relative to corresponding controls 
0 Gy 100% 62. 1 % 82.4% 87.8% 94.5% 
2.5 Gy 100% 37.4% 59.6% 72.7% 82. 1 % 
Enhancement ratio 1 . 7 1 . 4 1 . 2 1 . 1 
In a further set of experiments, Lin et al. (1979b) 
exposed DON and 3T3 cells (an established cell line 
derived from mouse embryonic fibroblasts) to DOC alone 
and in combination with gamma irradiation. Cells 
treated with DDC consistently showed lower levels of 
survival, which were even further reduced when the cells 
were exposed to radiation as well. Analysis of the 
survival curves of these two cell lines showed that DOC 
modified the slope as well as the shoulder of the curve. 
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They argued that the lowered survival of the DDC 
pretreated cells must be, at least in part due to their 
reduced ability to defend themselves against o2 related 
toxicity. 
Mitochondrial alterations 
In electron microscopy studies, Lin et al. (1979b) noted 
that DDC treated cells showed marked changes in the 
mitochondria. These included swelling with clearing of 
the mitochondrial matrix and the formation of myelin 
figures of mitochondrial membranes. Some mitochondria 
showed inhomogenous matrices and modified internal and 
external membranes which suggested a moderate degree of 
degeneration. Myelin figures were also present in the 
cytoplasm of DOC treated 3T3 cells. It was argued that 
these mitochondrial alterations are essentially similar 
to the pathology of cells exposed to hyperbaric oxygen, 
as described by Hughson et al. (1977). 
The mitochondrial changes noted would be consistent with 
the cells having lower levels of respiration and ATP 
production, which could have serious implications in the 
post irradiation-repair period. Another mitochondrial 
enzyme, cytochrome oxidase has been reported to be 
inhibited by DDC in vivo, possibly because of the fact 
that this enzyme is copper containing (Frank et al., 
1978). Inhibition of this enzyme could lead to 
increased o2 since mitochondrial electron transfer 
systems can generate superoxide (Nahl & Henger, 1978) . 
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Cytochrome oxidase can also act as a superoxide scavenger 
(Markossian et al., 1978) and therefore an inhibition of 
cytochrome oxidase might further add to the effect of SOD 
inhibition by DDC. 
Biphasic Toxicity of DDC 
The literature concerning this subject is summarised in 
Table 4.2. 
Table 4.2 A surmiary of previous work showing the biphasic toxicity of DDC 
Concentration : Low ---> 
Author/Experiment 
Rigas et al., 1979 
lymphocytes 
Non-toxic 
Westman & Midander, 1984 
Chinese hamster cells X 10-6M 
Maners et a 7. , 1985 
mouse fibroblasts 
Lin et a 7., 1985 
V79 cells 1 X l0-6M 
Heikkila et al., 1976 
Cristensen et al., 1974 
mouse (in vivo) 
Toxic 
1 X l0-4M 
2.9 X l0-8M 
1 X 10-SM 
0. 5 - 0. 6 g/kg 
High 
Non-toxic Toxic 
>l X 10-4M 3 X l0-3M 
5.8 X l0-7M l. 5 X 10-SM 
>l X 10-SM 1 X 10-3M 
1. 5 g/kg 
Rigas et al. (1979) observed a biphasic toxicity of DDC. 
These workers measured cell survival and RNA synthesis 
from [ 3H]-uridine incorporation in lymphocytes, monocytes 
and polymorphonuclear granulocytes following 2 hours 
46 Chapter 4 
incubation with various concentrations of DDC at 37°C. 
Low concentrations of DDC ( 1 x 1 o-9M to 2. 5 X 1 o- 6M) 
appeared to increase cell survival, while higher 
concentrations (2.5 X 10-5M) were toxic. As the 
concentration was increased further, toxicity decreased 
and cell survival reached a maximum around 2.5 X 10- 4M. 
At even higher concentrations, DDC became toxic again, 
and cell survival decreased again. The incorporation of 
[ 3HJ-uridine followed a similar course. 
Rigas et al. (1979) found that the first phase of 
toxicity (2.5 X 10-5M) could be partially reversed by the 
addition of 2.5 X 10-5M zncl 2 , but not by the addition of 
2.5 x 10-5M or 1 x ~o- 2M cuc1 2 . On the other hand, the 
inhibition of [ 3H]-uridine incorporation by 2.5 X 10-
3M 
DOC was not reversed by 2.5 X 10-5M or 1 X 10-2M ZnC1 2 , 
but was partially reversed by 1 X 10-2M Cucl 2 . 
These investigators argued that the inhibition of zinc 
metalloenzymes by DDC plays a crucial role in the first 
toxic phase, and inhibition of copper metalloenzymes in 
the second. They also argued that DDC may be 
biphasically toxic in vivo, as large doses of DDC ( 1. 5 
g/kg) have been given to mice without ill effects 
(Heikkila et al. I 1976), yet lower doses (0. 5 - 0.6 g/kg) 
were found to be toxic (Christensen et al., 1974). 
In a later experiment (Rigas et al., 1980) it was noted 
that radiosensi tization of human lymphocytes by DDC was 
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also biphasic, and that these phases coincided with the 
biphasic toxicity of DDC (1 X 10-5M and 1 X 10-3M). The 
group found that SOD was only inhibited in the second 
phase, and suggested that it may be a contributing cause 
of this radiosensitization. 
phase is not known. 
The mechanism of the first 
'Paradoxical' Toxicity 
In this regard, Rigas et al., ( 1980) maintain that DOC 
appears to differ from the 'paradoxical' toxicity of 
other radioprotective thiols, 
increasing their concentration, 
which is reversed by 
(Vergroessen et al., 
1967; Delrez & Firket, 1968; Sawada & Okada, 1970) and 
is due to tt2o2 produced through oxidation of the thiol by 
molecular o2 ( Tagaki et al. , 197 4) . Furthermore, in 
contrast to these thiols which are radioprotective at 
concentrations at which their toxicity has become 
reversed, DDC at similar concentrations is 
radiosensi ti zing and inhibits SOD. Nevertheless, the 
possibility that the mechanism of the first phase of 
toxicity and of its reversal is the same as that of the 
'paradoxical' 
excluded. 
toxicity of these thiols cannot be 
This first phase could be due to the 
formation of toxic metal chelates of the type DDC····Mn+, 
and that the reversal of toxicity at higher 
concentrations could be due to the formation of non-toxic 
metal chelates of the type DDC· ···Mn+.·· ·DDC (Rigas et 
al. , 1980) . 
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Westman & Midander ( 1984) showed that exposure to x 
10- 6M DDC for 90 minutes had no effect on the survival of 
Chinese hamster cells. As the DDC concentration was 
increased, the toxicity increased reaching a maximum at 1 
At concentrations above 
toxicity decreased until 3 X 1 a- 3M, where it increased 
again. 
Maners et al. (1985) demonstrated a bimodal toxicity 
curve using mouse fibroblasts exposed to DDC 
concentrations ranging from 2.9 X 10-8M to 1.5 X 10-5M. 
They showed 97% cell toxicity at 1 .5 x 10-5M, 15% 
toxicity at 5.8 X 10-7M and 94% toxicity at 2.9 X 10-8M. 
Lin et al. ( 1985) incubated V79 cells (derived from a 
Chinese hamster cell line) in medium containing DOC at 
concentrations ranging from 1 X 10-6M to 1 X 10-3M for 60 
minutes. They found that DDC was not toxic at a 
X 1 o- 6M, but when the concentration concentration of 
increased to x 10-5M, DDC became toxic. As the 
concentration was further increased, DOC became less 
toxic. At concentrations of 1 X 10-3M and greater, DDC 
again became toxic. 
When DDC was combined with other cytotoxic agents such as 
radiation, adriamycin, bleomycin as well as hyperthermia 
(exposure to 43°C) it was found that the biphasic nature 
of the toxicity remained, but was enhanced by the other 
agents (Lin et al., 1985). 
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DDC inhibits SOD 
Westman & Marklund (1980) showed a 95% inhibition of SOD 
after Chinese hamster cells were incubated with 3 X 10-
3M 
DOC for 90 minutes. This inhibition remained after DOC 
was removed by four successive medium changes. The SOD 
inhibition decreased with time, but was found still to be 
significant for a few hours after the removal of DOC. 
They found that DOC pretreated cells had an increased 
slope, the ratio of DO-CONTROL/o0 _00c being 1 .23 
indicating radiosensitization. 
DDC effect not dependent on po2 
Westman & Marklund (1983) again examined the question of 
the effect of DOC on radiation haemolysis of 
erythrocytes. They found that by exposing erythrocytes 
to 3 x 1 a- 3M DOC for 90 minutes at 37°C produced a 98% 
inhibition of SOD. After 24 hours, the SOD activity was 
still only 10% of the control level. The activities of 
catalase (CAT) and glutathione peroxidase (GPx) were 
unaffected by this DOC pretreatment. 
This pretreatment of cells with DOC followed by 4 
washings to remove DOC had very little effect on the 
glycerol haemolysis time (GLT50 ). Exposure to ionizing 
radiation led to a shortening of the GLT 50 , and this was 
dose related. Pretreatment with 1 X 10-3M DOC for 90 
minutes prior to irradiation in DOC-free medium resulted 
in a small, but not statistically significant 
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(ratio=1.04) decrease in slope when compared to the 
radiation only GLT50 curve, however the intercept values 
on the Y axis (GLT) were found to differ significantly 
(p<0.005). They concluded that the effect of DDC was 
additive to radiation rather than potentiating. When 
DDC remained on the cells throughout the experiment, they 
found that concentrations of 10-3M and lower had no 
effect additional to that which was seen after DDC 
pretreatment. h 1 10- 2M t However w en X DDC was presen 
during the whole experiment, an increased sensitivity to 
radiation was seen. 
The addition of exogenous SOD and CAT to these 
experiments did not protect the cells significantly 
against radiation haemolysis. It was argued that this 
suggested that in spite of a marked inhibition of SOD, no 
increase in susceptibility to glycerol haemolysis was 
seen, which indicated that o2 
medium are of negligible importance in the radiation 
haemolysis of erythrocytes. 
Westman & Midander (1984) irradiated V79 cells in argon, 
oxygen and air following 3 X 10-3 M DDC pretreatment for 
90 minutes. The clonogenic survival curves after 
irradiation yielded results as detailed in Table 4.3. 
The reduction of Do (reciprocal of the regression slope 
constant of the final straight portion of the survival 
curve) with DDC pretreatment was found to be 
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statistically significant in all oxygenation conditions, 
however there were no statistically significant 
differences between the dose modifying factors (DMFs) 
obtained in argon, air and oxygen. 
Table 4.3 D
0 
values for survival curves after treatment with radiation alone, 
or pretreatment with 1 X 10-3M DOC for 90 minutes prior to irradiation in 











1. 39 Gy 




1 . 15 Gy 
0.76 Gy 
1 . 51 
showed that the 
radiosensitizing effect of DDC was not dependent on the 
oxygen partial pressure at the time of irradiation as the 
DMF in argon, where no o2 is formed, did not differ from 
the DMF in air, and moreover an increase in oxygen 
concentration to 100% was not shown to enhance the DDC 
sensitization further. As the cells were returned to 
aerobic conditions immediately after irradiation, they 
suggested a long term post irradiation increase of 
radiation damage in DDC treated cells, and not an 
increase of immediate radiation damage. 
kinetic studies (Michael et al., 1973) 
Indeed, fast 
as well as 
studies demonstrating the importance of molecular oxygen 
for fixation of aerobic radiation damage (Samuni et al., 
1978) do not favour the participation of the superoxide 
radical in the immediate radiation effects. 
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Post irradiation treatment by DOC also sensitizes 
Westman & Midander ( 1984) treated V79 
10-3M DDC after exposure to radiation. 
cells with X 
They found that 
the radiosensitizing effect of DDC could be produced when 
DDC was added O. 5 or 2 hours, but not 20 hours after 
radiation. The authors concluded that superoxide 
dependent processes were involved in the mediation of 
delayed radiation damage, and that the temporary 
inhibition of SOD did not influence immediate radiation 
damage, but that long term delayed radiation damage was 
modified. In agreement with this conclusion are the 
results of Petkau & Chelack, ( 1976) where it was shown 
that addition of 
membranes. 
SOD after irradiation protected 
Stone et al. ( 1978) showed that 2. 4 x 1 a- 3M DDC added 
immediately after or 1 hour after irradiation resulted in 
a significantly greater amount of erythrocyte haemolysis 
than after radiation alone. This was seen as indicating 
that o2- was still present in sufficient 
quantities to do 
damage, or was being generated by other reactions. They 
offered a mechanism proposed by Packer & Winchester 
(1970) to substantiate this : 
Radiosensitization by DOC 53 
H20 --> e aq INITIATION 
e aq + 02 --> 02 
RSH + 02 --> RS + H02 (H202) 
RS + 02 --> RSOO 
RSOO + RSH --> RSSR + H02 (02 
- ) PROPAGATION 
RS + RSH --> RSSR 
RSSR + 02 --) RSSR + 02 
RS + RS --) RSSR TERMINATION 
The final product of this chain reaction is disulphide. 
The finding that gamma-irradiation of erythrocytes led to 
an increase of disulphide linkages and a decrease in free 
sulphydryl groups, (Sutherland & Phil, 1968) was 
consistent with this mechanism. Thus inhibition of SOD 
by DDC after irradiation could still lead to 
sensitization, should the reactions proposed above occur. 
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Chapter 5 
Radioprotection by DDC 
Many compounds can protect against the lethal effects of 
radiation not by directly affecting the radiosensitivity 
of the cells, but rather by causing vasoconstriction, or 
disturbing the normal metabolism. This may occur to 
such an extent that the oxygen concentration in critical 
organs is reduced, thus offering a measure of protection 
because cells in which the oxygen concentration is low 
are more resistant to sparsely ionizing radiation (Hall, 
1988). However, it must be emphasised that the 
compounds that act in this way, such as sodium cyanide, 
co, adrenaline, histamine and serotonin are not 
protectors per se. 
Sulphydryl compounds 
True protectors are generally sulphydryl-containing 








In 1949, Patt et al. discovered that cysteine could 
protect mice against lethal effects of X-irradiation when 
large amounts were injected prior to exposure. At about 
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the same time, cysteamine was also found to protect 
animals from total body irradiation (Patt, 1953). 
Cysteamine 
Although these compounds were too toxic for clinical use, 
their discovery prompted great interest in finding other 
non-toxic radioprotective compounds, especially after the 
explosion of atomic bombs at Hiroshima and Nagasaki 
during World War II. 
Many similar compounds have been tested and found to act 
as radioprotectors. A common feature of these compounds 
is a free SH group at one end of the molecule and a 
strong basic function such as an amine at the other end 
separated by a chain of two or three carbon atoms. 
Competition with oxygen for fixation of damage 
It was shown in bacteria that protection by sulphydryl 
compounds was dependent on oxygen concentration (Alper, 
1962), a phenomenon which was later demonstrated in 
mammalian cells both in vitro (Chapman et al., 1973) and 
in vivo (Harris & Phillips, 1971). It is thought that 
sulphydryl compounds work by scavenging free radicals 
produced by ionizing radiation. 
combine with oxygen: 
These radicals may 
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F 
forming a highly reactive radical product, which can 
seriously damage biologically sensitive molecules. 
Sulphydryl compounds block this process by reacting with 
free radicals in competition with oxygen (Koch & Howell, 
1981). The protective effect of sulphydryls therefore 
tends to parallel the oxygen effect, being maximal for 
sparsely ionizing radiation and minimal for densely 
ionizing radiation. It might be predicted that with 
effective scavenging of all free radicals, the largest 
possible dose reduction factor (ORF) i.e .. 
ORF= 
dose of radiation in presence of drug 
dose of radiation in absence of drug 
(to produce a given level of lethality) 
would equal the oxygen enhancement ratio (OER) with a 
value of 2.5 to 3.0 (Hall, 1988). 
A second mechanism 
suggested by Durand 
of thiol 
(1983), 
radioprotection has been 
whereby thiols deplete all 
the oxygen and thereby induce anoxia. Durand & Olive 
(1989) have recently shown that thiol manipulation 
markedly influences the oxygenation status of cells (due 
to thiol oxidation reactions) and that this mechanism is 
of greater significance at lower oxygen tensions. 
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WR-2721 
In the years that followed World War II, the Walter Reed 
Army Hospital in Washington D. C. synthesised more than 
2000 compounds in an attempt to find the 'perfect 
radioprotector', one that would protect without 
debilitating side effects. At an early stage it was 
found that the toxic side effects of these compounds 
could be reduced if the sulphydryl group was 'covered' by 
a phosphate group. One of the most effective of these 
compounds that were developed in this period was WR-2721 
(Hall, 1988). 
NH2 ~- (CH2 ) 3 ~- NHCH2CH2SP03H2 
WR-2721 
WR-2721 was found to give good protection to the blood 
forming organs, with a ORF of 2.7, approaching the 
theoretical maximum value of 3 (Yuhas et al., 1980). 
In radiotherapy a radioprotector, to be effective, has to 
protect normal tissues to a greater extent than tumour 
tissue. Successful protectors should also be 
hydrophilic, since lipophilic compounds would not show 
any differential uptake between tumour and normal cells 
(Hall, 1988). WR-2721 has been shown to be actively 
concentrated by normal tissues, yet only be passively 
absorbed by solid tumours (Yuhas, 1980). 
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A differential protection with WR-2721 has been shown in 
small laboratory animals irradiated with a large single 
dose of X-rays (Yuhas, 1973). It has not unequivocally 
been shown that there is a similar differential 
protection when tumours are irradiated with multiple 
small radiation doses. However phase I toxicity trials 
with WR-2721 in humans showed dose limiting toxicities 
including hypotension, hypertension, emesis, somnolence 
and allergic reactions (Blumberg et al., 1982; Glick et 
al., 1982) . These side effects tended to limit the 
amount of drug given to levels lower than necessary to 
give maximum protection. 
Chemical radioprotectors appear to be more efficient in 
protecting tissues from low LET compared to high LET 
radiation (Sigdestad et al., 1975; Sigdestad et al., 
1976). Sigdestad et al. (1986) showed that WR-2721 was 
a more 
radiation. 
efficient as a protector against low LET 
This could be due to greater influence of 
free radical 
because of 
scavenging and/or hydrogen ion donation 
* LET differences in subcellular dose distribution 
* The degree to which radiolysis of water affects 
cell killing by radiations of different qualities. 
The induction of hypoxia 
demonstrated by Durand & Olive 
by thiol compounds 
( 1989) could lead to 
as 
an 
increased survival after low LET compared to high LET 
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radiation because of the greater oxygen effect on low LET 
radiation injury. 
Diethyldithiocarbamate 
In 1953 Bacq found that diethyldithiocarbamate (DOC) 
offers protection to mice against the lethal effects of 
ionizing radiation. The protective properties of DOC 
were found to be as good as cysteamine (Alexander et al., 
1955), one of the best chemical radioprotectors known at 
that time. The relationship between the chemical 
structure of dithiocarbamic acid and its derivatives and 
their radioprotective action has been extensively studied 
by Van Bekkum ( 1956). Ammonium dithiocarbamic acid, 
sodium dimethyldithiocarbamate and Na-DDC gave maximum 
protection, whilst further substitution at the N or S 
position decreased the radioprotective properties. The 
corresponding disulphide of DOC, tetraethylthiuram 
disulphide (disulfiram), as well as tetraethylthiuram 
monosulphide did not have any radioprotective action. 
Stromme (1965b) studied the metabolism of DOC and 
disulfiram in rats. It was found that upon absorption, 
disulfiram immediately becomes converted to DOC. This 
DOC (either formed in vivo from disulfiram or 
administered as such) was found to be metabolised at a 
high rate, the main end products being the S-glucuronide 
of DOC, inorganic sulphate and carbon disulphide. It 
was shown that DOC is an obligatory intermediate in the 
metabolism of disulfiram, and thus it appeared 
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contradictory that only DDC and not disulfiram possessed 
radioprotective qualities. Stromme & Eldjarn (1966) 
used 35s-labelled compounds in mice to study the 
metabolism of DDC and disulfiram. They found that DDC 
is metabolised along three main routes : 
* conjugation with glucuronic acid 
* oxidation to sulphate 
* decomposition to diethylamine and volatile carbon 
disulphide, which is eliminated via the lungs. 
A marked difference in organ distribution was found which 
was in agreement with results of other radioprotecti ve 
S-containing compounds. The highest amounts were shown 
in plasma, liver and kidney, whereas the lowest amount 
was found in the brain. Organs which play an important 
role in the radiation syndrome such as bone marrow, 
spleen and intestinal mucosa showed intermediate amounts 
10 minutes after 15 mg 35s-labelled DDC was injected i.p. 
It was shown by Stromme & Eldjarn (1966) that initially 
(during the first 40 minutes after injection) high 
concentrations of free unmetabolised thiol were found, 
and during the following 40 minutes, this concentration 
decreased rapidly. At the same time, the concentration 
of the S-glucuronide of DDC, sulphates and protein bound 
metabolites increased. 
The total concentrations of 35s found in tissues after 
disulfiram administration were found to be only 
1/ 10 -
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1 / 20 of that found with DDC. This may explain why 
disulfiram does not show any radioprotective qualities. 
No free DDC was found in tissues at the time of exposure 
to irradiation after disulfiram administration. Stromme 
& Eldjarn ( 1966) argued that the resorption of water 
insoluble disulfiram was so slow that the organism was 
capable of metabolising this compound fast enough to 
prevent any measurable build up of disulfiram or DDC. 
Radioprotection due to non protein-bound DDC 
At that time the mechanism of radioprotection by DDC was 
unclear. In vitro studies had failed to demonstrate 
any mixed disulphide formation of DDC with biological low 
molecular weight di sulphides ( Eldj arn & Pihl, 1960) and 
with s-s groups of proteins (Stromme, 1965a). In vivo 
data however, suggested that some mixed disulphide 
formation occurred on both the soluble and structural 
proteins. This was thought probably to be due to an 
initial oxidation of DDC to disulfiram, which is known to 
have a great ability for oxidising and forming mixed 
di sulphides with endogenous thiol groups (Stromme, 
1965a). However, in contrast with the considerable 
amounts of protein-bound sulphur recovered from mice 
treated with other radioprotective sulphur containing 
compounds, (Eldjarn & Pihl, 1956; Eldjarn & Pihl, 1960) 
the amounts of sulphur detected after DDC administration 
represent only a minute fraction of the total sulphur 
given. This, together with the fact that disulfiram 
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under conditions where no radioprotection was 
demonstrated, gave rise to the same amount of protein-
bound sulphur as that obtained with DDC made it unlikely 
that protein-bound metabolites played any important role 
in its radioprotective action. 
Stromme & Eldjarn (1966) argued that, of the metabolites, 
the free (i.e. non protein-bound) thiol, DDC seems to be 
the most likely immediate active agent in 
radioprotection, and this would explain why disulfiram 
fails to protect as in contrast to the amounts of free 
thiol after DDC administration, there is a complete 
absence of free thiol after disulfiram administration. 
Duration of DDC action 
Craven et al. ( 1976) determined the time sequence of 
absorption and elimination of DDC and compared this to 
its duration of action. 
35s-labelled DDC was given by 
stomach tube to Wistar rats at a rate of 25 mg/kg. 
After 15 minutes the DDC concentration in the plasma was 
11 . 3 µg/ml. Analysis of the plasma at this time showed 
equal quantities of free DDC and dithio-S-glucuronide 
together with a small amount of inorganic sulphate. 
Following oral administration of 
35s-labelled DOC, it was 
rapidly excreted, 60% of the dose being cleared in 3 
hours. By 72 hours, 96% of the administered dose could 
be accounted for in the excretory products. 50% of this 
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was via the lungs in the form of carbon disulphide and 
most of the remainder in the urine. 
The duration of DDC action was measured by the ability of 
DDC to prolong the sleeping time induced by 
pentabarbitone sodium (45 mg/kg i.p.). DDC was 
administered orally to mice at various times before the 
injection of pentabarbi tone and the sleeping time was 
recorded for each animal. Prolongation of sleeping time 
was maximal when DDC was administered 60 minutes before 
pentabarbitone sodium, and no prolongation was noted when 
this time interval was three hours, showing that the 
duration of action of DDC is not in excess of three 
hours, and at this time over half of the DDC dose had 
been eliminated. 
Ionizing radiation can induce haemolysis in red blood 
cells. Bartosz & Leyko (1981) examined the effect of 
various free radical scavengers on radiation damage to 
red blood cell membranes. When comparing the effect of 
these scavengers, the relative haemolysis was expressed 
by : 
haemolysis of samples irradiated with protector 
Hrel = 
haemolysis of samples irradiated without protector 
Erythrocytes were incubated with DDC for 2 hours at 37°C 
and then irradiated with a 60co source to a dose of 5 Gy. 
They showed no radiosensi tization as suggested by Stone 
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et al. (1978) , but instead radioprotection, as shown in 
Table 5.1. 
Table 5. l The effect of DOC (present during irradiation) on the radiation 
induced haemolysis of bovine erythrocytes. 
DOC cone 8rel 
[mM] % 
1 . 0 42.7 ± 6.0 
2.5 35.8 ± 1 . 0 
5.0 61. 4 ± 1 . 8 
Cysteine 5.0 82.6 ± 0.4 
Evans et al. ( 1983a) extended their work to the in vivo 
situation, where they showed that the Lo50 ; 30 in F1 
hybrid (C57/El X EALE/c) mice was increased from 7.8 Gy 
to 14 Gy when non-toxic concentrations of DDC were 
injected prior to total body irradiation (TEI). 
results are presented in Tables 5.2 and 5.3. 
Their 
Table 5.2 LD50130 
as a function of time of injection of 1000 mg/kg DOC in Fl 
hybrid (C57/B1 X BALB/c) mice. 
Time of injection LD50/30 (Gy) 95% Confidence 
1 hr after TEI 8.6 ( 8.2 - 9.0) 
2 hr before TEI 14.0 (13.4 - 16. 4) 
30 min before TEI 13. 4 ( 12. 9 - 13. 9) 
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Table 5.3 LD
50130 
as a function of DDC dose injected 30 minutes before total 
body irradiation in Fl hybrid (C57/Bl X BALB/c) mice. 
Dose of DDC (mg/kg) LDso/30 (Gy) 95% Confidence 
0 7.8 ( 7. 1 - 8.2) 
500 7.7 ( 7.0 - 8.4) 
1000 14.9 (14.3 - 15. 5) 
1400 13.4 ( 12. 9 - 13. 9) 
An LD50/7 of 17.0 ( 1 5. 6 18. 9) Gy for death by the 
gastrointestinal syndrome was obtained with no DDC 
present and 16.5 (16.2 - 16.8) Gy when 1000 mg/kg DDC was 
injected 30 minutes prior to irradiation, suggesting that 
DDC offers no protection against the gastrointestinal 
syndrome in these mice. 
Using 35s-labelled DDC, Evans et al., (1983a) showed that 
higher levels of DDC were obtained in kidney, lung and 
bone marrow compared to tumour tissue, a result 
previously demonstrated by Stromme & Eldjarn (1966). It 
was argued that this data supports a differential uptake 
in normal versus tumour tissue. 
In an effort to show that bone marrow cells were 
protected by DDC, Evans et al. (1983a) performed a 
standard spleen colony assay (Till & McCulloch, 1961) 
where survival fractions are based on injecting bone 
marrow cells, from mice which have received graded doses 
of total body irradiation, into ten recipient mice and 
determining the number of spleen colonies eight days 
later. Their results showed an absence of a shoulder on 
the survival curves for spleen colonies in mice which 
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were treated with 1000 mg/kg DOC, injected 30 minutes 
prior to irradiation as well as for mice without DDC 
pretreatment. However, they showed an increase in Do 
from O. 8 Gy with irradiation alone to 1. 2 Gy with DOC 
pretreatment giving a DMF of 1 .5. 
DDC stimulation of stem cells 
Allalunis-Turner & Chapman (1984) also performed a spleen 
colony assay and observed large increases in spleen 
colonies in C57/B1/10J mice after a treatment of various 
doses of DDC without irradiation (Colony enhancement 
ratio, CER = 3.9). When spleen colony assays for DDC 
and irradiation were normalised to account for this 
observed enhancement of colony forming uni ts with DDC 
alone, the DMF after a single dose of 30 mg DOC ranged 
from O. 9 to 1 . 1 as opposed to 1.4 to 2.9 with 
non-normalised results. 
The same investigators suggested that the difference 
between the DMF obtained in this study and the large DMFs 
reported for DDC in other studies could be due to the 
resolution of DDC effects into a drug dependent 
stimulation of stem cells and a true radioprotective 
effect. It was therefore possible to overestimate the 
protective effect of DDC. 
The mechanism of DDC stimulation of haematopoetic cells 
has yet to be determined. Allalunis-Turner & Chapman 
(1984) gave, as a possible explanation for the ability of 
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DOC to protect cells, its ability to trigger cells into 
cycle, possibly into a more radioresistant phase, an 
effect that has been documented for endotoxin, a 
non-thiol radioprotector (Queensberry et al., 1973; Smith 
et al. , 1966) . 
Multiple doses of DDC ( 15 mg at 48 hr, 24 hr and 15 
minutes prior to irradiation) were not as effective as a 
single dose, producing little protection and little 
enhancement of colony forming uni ts. It was suggested 
that bone marrow could become refractory to the effects 
of DOC, and while this would not affect the potential 
usefulness of DDC in single dose, whole body irradiation 
schemes, the use of DOC in fractionated radiotherapy 
would be compromised (Allalunis-Turner & Chapman, 1984). 
Evans (1985), using a similar spleen colony assay with F1 
hybrid (C57/B1 X BALB/c) and C3H/Km mice was unable to 
demonstrate any stimulation of the bone marrow by DOC 
alone. He showed that DDC protected bone marrow in F1 
hybrid mice with a DMF of 1. 5. DOC offered a lesser 
degree of protection when similar experiments were 
performed in hypoxic conditions (mice were bathed in 5.5% 
oxygen in nitrogen for 5 minutes prior to and during 
irradiation, which without DDC resulted in an oxygen 
enhancement ratio (OER) of 2.3, indicating that an 
hypoxic state did in fact occur following this 
treatment). (DMF = 1 .2). 
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A similar result was obtained with the LD50130 assay 
after total body irradiation, where a DMFAIR of 1.9 was 
obtained compared to a DMFHYPOXIA of 1 .2 in animals 
breathing the 5.5% oxygen mixture. 
Radioprotection with concomitant tumour 
radiosensitization 
In a further experiment, Evans (1985) exposed C3H/Km mice 
bearing a RIF-1 fibrosarcoma to total body irradiation in 
air or hypoxia. Following irradiation, the tumour was 
excised and an in vitro cell survival assay used to 
determine the radiation response of the tumours. Bone 
marrow was also removed from these mice and used in a 
spleen colony assay. It was found that DDC, as in the 
F1 hybrid mice, protected the bone marrow with a DMF of 
2.1 in air breathing animals. 
In the tumours however, DDC pretreatment resulted in 
sensitization by a factor of 2.6 in air breathing mice, 
and by a factor of 13 in mice breathing the 5.5% oxygen 
mixture. 
demonstrated 









radiosensitization (hypoxic>aerobic) strongly suggested a 
large therapeutic gain factor, and had a direct 





Apparently contradictory findings, namely that DDC can 
act as a radiosensi tizer or as a radioprotector, have 
been demonstrated by various investigators over the last 
few years. The major contributions to this debate in 
the literature have been reviewed in the last two 
chapters. 
It is possible that these two positions can be 
reconciled. There is evidence that DDC inhibits SOD, 
and that SOD is an important antioxidant enzyme that can 
protect cells against the damaging effect of radiation 
produced oxygen radicals. However, there is also 
extensive evidence that thiols, such as DDC can protect 
cells by competing with oxygen for the fixation of oxygen 
induced damage, by scavenging radiation induced radicals, 
or by inducing anoxia in the tissues. 
In the present work, it is 
radiosensi tization can occur as 
hypothesised 
a result of 
that 
SOD 
inhibition by DDC, but can be masked by a radioprotective 
effect if the tissue levels of DDC are too high at the 
time of irradiation. 
Thus, to resolve the apparent discrepancies, it is 
postulated that the introduction of time delays between 
DDC administration and radiation may reveal definitive 
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information as regards the action of DOC. This thesis 
describes in vitro and in vivo investigations along these 
lines. 
The first work done in this regard concerned the 
measurement of SOD and other antioxidant enzymes at 
various times after DOC administration. 
In the presentation of these investigations, it was 
decided to present the methods and results of each enzyme 
study separately, followed by a general discussion at the 
end of the chapter. 
The hypothesis was also tested in vivo using the tumour 
growth delay assay. These investigations form the major 
part of this thesis, and in the discussion of this 
section, the hypothesis is developed further. 
Many intrinsic problems in the analysis of growth delay 
assays came to light during these investigations. These 
problems together with an alternative method of analysing 
this kind of data are presented in Chapters 8 - 10. 
The effect of a time delay between DDC administration and 
radiation on the Lo50130 is exam
ined in Chapter 11. 
In vitro studies of the effect of DDC on mouse melanoma 
cells to both radiation and hyperthermia are reported in 
Chapters 12 and 13. 
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DDC and the enzymatic defence against 
oxygen toxicity 
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In this chapter studies which examine the effect of DDC 
on enzymes involved in the defence against oxygen 
toxicity are described. 
Objectives 
* To confirm that DDC inhibits superoxide dismutase 
(SOD). 
* To examine the time course of this inhibition. 
* To examine the effect of DDC on other enzymes in 
the oxygen defence system, viz. catalase and 
glutathione peroxidase. 
Methods 
Superoxide dismutase assay 
The method of Misra and Fridovich ( 1972a) was used to 
measure SOD activity. The assay is based on the 
autooxidation of adrenaline to an adrenochrome at pH 
10. 2. 
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Adrenaline is stable in acidic solutions, but oxidizes to 
adrenochrome with increasing facility as the pH is 
raised. 
It has been proposed that the autooxidation of adrenaline 
is initiated by traces of heavy metals present as 
contaminants in reaction mixtures. Indeed, EDTA has 
been demonstrated to inhibit this autooxidation by Misra 
& Fridovich ( 1972a) who also showed that SOD inhibited 
this reaction to a maximum of 91 % at pH 1 0. 2. They 
showed that virtually all the oxidation at this pH was 
produced by an o2 
involvement of o2 
dependent pathway, and that the 
diminished with decreasing pH, 
becoming undetectable below pH 8. 5 . They proposed two 
alternative mechanisms of adrenaline oxidation, each of 
which assumed greater relative importance depending on 
the pH. 
At high pH, where RH 3 represents ad
renaline, R 
represents adrenochrome and Men represents a heavy metal 
cation, the oxidation could be initiated by traces of 
heavy metal cations (reaction a). 




+ Men-1 (a) 
RH3 + 02 --> RH2 + 02 
- + H+ (b) 
RH2 + 02-
+ H+ --> RH + H202 ( C) 
RH + 02 --> R + 0 2 
- + H+ (d) 
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Superoxide could also initiate the oxidation and start a 
chain reaction: 
Clearly SOD should strongly inhibit the formation of 
adrenochrome by reacting with o2-. 
Misra & Fridovich (1972a) argued that the effect of EDTA 
on this mechanism would be twofold. Firstly it would 
inhibit the rate of adrenaline oxidation due to chelation 
of heavy metal cations in reaction a. Secondly it would 
emphasise the role of o2 in adrenaline oxidation 
(reaction e), with a concomitant increase in sensitivity 
towards SOD. They argued that this would occur because 
of the EDTA-metal cation complex reacting to produce o2 -
as discussed by McCord & Fridovich (1969b). EDTA had no 
effect on the activity of SOD in other assay systems. 
At low pH, Misra & Fridovich ( 1972a) proposed that the 
organic radical generated by the initiating event could 
lead to adrenochrome formation by a series of dismutation 
reactions such as : 
--) 
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Here SOD would not inhibit adrenochrome formation. The 
reduced metal cation generated in reaction (a) alone 
could be reoxidised by reaction with oxygen: 
( i) 
Thus an assay for superoxide dismutase was described. 
The production of adrenochrome in reaction mixtures 
containing 3 X 1 o- 4 M adrenaline, X 1 o- 4 M EDTA and 
0. 05 M sodium carbonate buffer at pH 10. 2 at 30°C was 
followed at 480 nm. 
Preparation of tumour samples after 
intratumoural administration of DDC 
Male BALB/c mice were inoculated with a transplantable 
rhabdomyosarcoma in the right hind gastrocnemius muscle 
as described in Appendix 2. 
DDC solutions for intratumoural administration were 
prepared as described in Appendix 2. 
Five tumour-bearing mice were used in each group, 4 
having been injected with 20 µl DDC intratumourally at 
doses of 50, 100 and 150 mg/kg body weight, the remaining 
mouse serving as a control. One to twenty four hours 
after DDC administration, the mice were sacrificed and 
the tumours excised. Non-necrotic tumour tissue was 
homogenised in a Potter-Elvehjem homogeniser in 5 ml 
potassium phosphate/EDTA buffer, which was then clarified 
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by centrifugation in a Sorvall RC-SB centrifuge at 30 000 
X g for 30 minutes at 5°C. 
Superoxide dismutase extraction 
The method of Sykes et al. (1978) for SOD extraction was 
used. Direct assay of SOD was not possible as extracts 
of homogenised tissue were often too highly coloured by 
haemoglobin, thus further clarification of the sample was 
necessary. 
Following tissue homogenisation and centrifugation, the 
supernatant fluid was removed and treated with 0.25 
volume ethanol and O. 15 volume chloroform, both chilled 
to 5°C. This precipitated the haemoglobin complexes, 
which were removed by centrifugation for 30 minutes at 30 
000 X g at 4°C in a Sorvall RC-SB centrifuge. 
The supernatant was removed and K2HP04 was added to a 
final concentration of 30% (w/v) and stirred using a 
vortex mixer until all the salt had dissolved. The 
mixture was centrifuged for 20 minutes at 17 210 X g at 
4°C to bring about a clean separation of the phases. 
The lighter phase, essentially water and ethanol, 
containing the bulk of the enzyme was carefully removed. 
The enzyme was precipitated by the addition of 0.75 
volume cold acetone (-20°C). This mixture was 
centrifuged for 30 minutes at 17 210 X g at 4°C, and the 
acetone supernatant discarded, leaving the SOD containing 
precipitate which was resuspended in O. 75 ml distilled 
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water. This was allowed to stand at 5°C overnight to 
ensure complete solubilisation of the enzyme whereafter 
it was centrifuged for 30 minutes at 17 210 X g at 5°C to 
remove any traces of flocculated material. The 
water-clear supernatant constituted the tumour extract 
and was assayed immediately. 
Measurement of superoxide dismutase activity 
The reagents used are detailed in Appendix 1. 
A standard solution of superoxide dismutase (SOD) was 
prepared in water using bovine erythrocyte SOD (Sigma, 
St. Louis, Mo.), the activity of which was 28 000 
units/ml. EDTA buffer was oxygenated by 
bubbling o2 gas through the solution for 5 min
utes. 
The reaction was started by adding a 0.0125 ml stable, 
acidic aliquot of adrenaline to 1 .1 ml buffer in a quartz 
glass cuvette. The rate of adrenochrome formation was 
then measured spectrophotometrically at 480 nm at 30°C 
with a Pye-Unicam SP8-400 double beam spectrophotometer. 
A standard curve for SOD activity using a 0.28 units/µl 
SOD solution was generated by plotting the percentage of 
inhibition of the rate of change of the absorption of 
adrenochrome at 480 nm against SOD concentration (Fig 
7. 1 ) . 
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Figure 7. 1 The standard curve for superoxide dismutase concentration vs the 
inhibition of the rate of change of absorption of adrenochrome at 480 nm. 
Tumour SOD activity was measured by adding 0.02 ml tumour 
extract to 1. 08 ml buffer prior to the addition of the 
adrenaline aliquot. The subsequent reduction in the 
rate of formation of adrenochrome was then used to 
calculate SOD activity. 
Figure 7.1 shows that the graph of percentage inhibition 
of the rate of adrenochrome formation as determined by 
absorption changes at 480 nm against SOD concentration is 
not linear, but reaches a plateau at about 0.6 units SOD 
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(or 50% inhibition of the rate of adrenochrome 
formation). Three or four replicates of SOD activity 
for each tissue extract were made, and volumes of buffer 
and sample were adjusted to give readings in the linear 
part of the standard curve, that is, such that there was 













spectrophotometer using the method of Bohlen et al. 
( 1973) as this method allows protein determinations in 
the nanogram range. The method is described in Appendix 
1. Calculation of SOD content of tumour samples was 
performed in terms of units of enzyme per mg protein. 
Results 
Tumours used in this experiment ranged in size from 0.201 
to 1.327 cm3 with a mean volume of 0.471 cm
3 ± 0.196 cm3 
(mean± SD). Care was taken to exclude necrotic tissue 
from the samples. 
demonstrable effect 
The size of the tumours had no 
on SOD activity in otherwise 
untreated (control) tumours. Linear regression analysis 
was performed on the tumour size against SOD activity, 
and a correlation co-efficient of r=0.1323 obtained. 
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Tumour superoxide dismutase activity 
Untreated (control) mice had mean SOD activities ranging 
from 46.6 to 101.4 units/mg protein with a mean activity 
of 77.6 ± 16.2 units/mg protein (mean± SEM). 
Analysis of SOD activity up to 24 hours after doses of 
50, 100, and 150 mg/kg DOC showed that DOC reduced the 
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Figure 7.2 Tumour SOD activity after intratumoural administration of 50 mg/kg 
DDC. Maximum inhibition of SOD activity (87.7%) was achieved two hours after 
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TIME (hours) AFTER DOC ADMINISTRATION 
Figure 7.3 Tumour SOD activity after intraturnoural administration of 100 
mg/kg DDC. Maximum inhibition of SOD activity (92.5) was achieved one hour 
after DDC administration, and the SOD activity remained low up to 24 hours 
after DDC administration. Bars represent standard deviation. 
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Figure 7.4 Tumour SOD activity after intratumoural administration of 150 
mg/kg DDC. The inhibition of SOD activity after this dose of DDC was not as 
great as seen with lower doses. Bars represent standard deviation. 
Table 7.1 shows the inhibition of SOD activity as a 
percentage of control SOD activity where SOD was 
inhibited by DOC treatment. Where a significant 
difference at or close to the 5% level was noted, the t 
values and probability are tabulated. 
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Table 7.1 SOD activity as a percentage of control SOD activity in DDC treated 
tumours. (N.S. = not significant), t-values read at 29 degrees of freedom. 
DDC dose Time between % inhibition significance 
DDC and assay of control 
SOD activity 
50 mg/kg hr 67.3 N.S. 
50 mg/kg 2 hr 87.7 t=2. 132, p<0.05 
50 mg/kg 4 hr 61 . 9 N.S. 
100 mg/kg hr 92.5 t=2.253, p<0.05 
100 mg/kg 2 hr 88.7 t=2.158, p<0.05 
100 mg/kg 4 hr 78.5 t=1 .908, N.S. 
100 mg/kg 6 hr 43.4 N.S. 
100 mg/kg 12 hr 91. 7 t=2.232, p<0.05 
100 mg/kg 24 hr 70.6 N.S. 
150 mg/kg hr 54.5 N.S. 
150 mg/kg 2 hr 36.2 N.S. 
150 mg/kg 4 hr 48.8 N.S. 
150 mg/kg 6 hr 76.2 N.S. 
Exposure to 50 mg/kg DDC caused a decrease in SOD 
activity at 1, 2 and 4 hours after DDC administration, 
the 87.7% decrease at 2 hours being significant at the 5% 
level (Fig. 7.2 Table 7. 1). Six hours after DDC 
administration, SOD activity had returned to control 
levels. 
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When a higher DDC dose (100 mg/kg) was administered, the 
inhibitory effect of DDC was even greater, and a 92% 
inhibition of SOD activity was noted hour after DDC 
administration. SOD activity remained low up to 24 
hours after DOC administration, where it was still only 
29.4% of control activities (Fig. 7.3 ; Table 7.1). The 
activities of SOD at 1, 2 and 12 hours after treatment 
were found to be significantly different from control 
activities at the 5% level. 
When the dose of DDC was further increased to 150 mg/kg, 
DOC also caused a reduction in SOD activities, but this 
was not as great as when a lower dose of DOC was 
administered (Fig. 7.4 Table 7.1). The maximum 
inhibition of SOD activity noted at this DDC dose was 
76.2% at 6 hours after DDC administration. 
The data obtained 
inhibition of SOD 
in the present work shows that 
does not appear to be linearly 
dependent on DDC concentration. 
Methods 
Glutathione peroxidase assay 
Glutathione peroxidase was first discovered in 
erythrocyte lysates as a consequence of its ability to 
protect haemoglobin from oxidative breakdown (Mills, 
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1957). It is made up of 4 protein subunits, each of 
which contains atom of selenium at its active site. 
Glutathione is a substrate for the enzyme. 
Glutathione peroxidase (GPx) has been shown to catalyse 
detoxification with high specificity the 
peroxide by the oxidation 





The assay method of Paglia & Valentine ( 1967) measures 
the rate of GSH oxidation by H2o2 as catalysed by GPx 
present within the tissue sample. Rather than measure 
the progressive loss of GSH, however, this substrate is 
maintained at a constant concentration by the addition of 
exogenous glutathione reductase (GSSG-r) and NADPH, so 
that any GSSG formed is immediately converted to the 
reduced form. 
GPx GSSG-r 
> 2H20 + GSSG ~> 
2GSH 
NADPH NADP 
To prevent decomposition of H2o2 by catalase in the 
tissue samples, azide, a catalase inhibitor is added to 
the reaction mixture. 
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The rate of GSSG formation is then measured by following 
the change in absorbance of the reaction mixture at 340 
nm as NADPH is converted to NADP. The enzymatic 
activity of GPx in this reaction mixture was found to be 
maximal at pH 8.0 with negligible activities below pH 6.0 
and with a rapid increase in the non-enzymatic oxidation 
of GSH above pH 7.0 (Paglia & Valentine, 1967). 
The method used in this work was a modification of Paglia 
& Valentine (1967) as made by Lawrence & Burk (1976) 
which was more sensitive to the enzymatic oxidation of 
GSH with H2o2 as substrate. 
Preparation of tissue samples after 
intratumoural administration of DDC 
Male BALE/ c mice were inoculated with a transplantable 
rhabdomyosarcoma in the right hind gastrocnemius muscle 
as described in Appendix 2. 
DDC solutions for intratumoural administration were 
prepared as described in Appendix 2. 
Four tumour-bearing mice were used in each group. They 
were injected with 20 µl DDC intratumourally at a rate of 
0. 5, 50 and 250 mg/kg body weight. The control mouse 
was injected with 20 µl 0.9% saline. One or four hours 
after DDC administration, the mice were sacrificed and 
the tumour, liver and normal gastrocnemius (left hind 
leg) muscle were excised. These tissues were 
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homogenised in a Potter-Elvehjem homogeniser in 2 ml 1 O 
mM potassium phosphate buffer at pH 8.0 which was 30 mM 
in KCl. The supernatant, after centrifugation for 20 
minutes at 4°C at 17 210 X g in a Sorvall RC-5B 
centrifuge was used as the enzyme source in this assay. 
Measurement of glutathione peroxidase activity 
The reagents used are detailed in Appendix 1. 
The total reaction volume was 2 ml and consisted of 0.5 
ml potassium phosphate buffer (pH 7.0); 0.2 ml EDTA; 0.2 
ml NaN3 ; 0.2 ml NADPH; 
µl GSSG-reductase; 0.2 ml GSH; 
0. 489 ml H2o and O. 2 ml H2o2 in a 3 cm
3 quartz glass 
spectrophotometer cuvette. 
All reagents except the enzyme source and the hydrogen 
peroxide were added prior to each experiment. The 
enzyme source (0.01 ml) was added to the sample cuvette 
and allowed to incubate for 2 minutes at room 
temperature, before initiation of the reaction by the 
The reference cuvette 
contained all reagents present in the sample cuvette, but 
the enzyme source was replaced by an equal volume of 
distilled water. 
The absorbance at 340 nm (measured using a Pye Unicam 
SP8-400 spectrophotometer) was recorded for 3 minutes and 
the activity of the enzyme was calculated from the 
absorbance change per minute. Enzyme units were defined 
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as the number of µmoles of NADPH oxidised per mg protein, 
and were calculated on the basis of a molar absorptivity 
for NADPH at 340 nm of 6.22 X 10- 6 (Horecker & Kornberg, 
1948) as follows 




2 ml 1 
X -~-~----- X ~----~~-------------
sample vol. mg protein/ml of sample 
Protein was measured spectrophotometrically using a 
Pye-Unicam SPS-400 double beam spectrophotometer by the 
method of Lowry et al., (1951) (Appendix 1). 
Results 
Tumours used in this experiment ranged in size from 0.271 
to 1.416 cm3 with a mean volume of 0.663 cm3 ± 0.250 cm3 
(mean ± SD). Linear regression analysis was performed 
on the tumour size against GPx activity in saline treated 
(control) tumours, and a correlation coefficient of 
r=0.6299 (p>0.1, 3 OF) obtained. It was therefore 
concluded that no relationship between tumour size and 
tumour GPx activity could be demonstrated. 
Tissue glutathione peroxidase activity 
Table 7 .2 shows that in saline treated (control) mice, 
GPx activity in the liver was about six fold greater than 
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in the tumour and twenty fold greater than in the leg 
muscle. 





Tumour 0.041 ± 0.008 
Muscle 0.013 ± 0.006 
Liver 0.240 ± 0. 096 
95% confidence 
0.026 - 0.056 
0.001 - 0.025 
0.052 - 0.427 
Analysis of glutathione peroxidase activity 1 hour after 
intratumoural administration of DOC showed a slight 
decrease of GPx activity at a dose of O. 5 mg/kg and 50 
mg/kg DOC, but not at a dose of 250 mg/kg in the tumour, 
leg muscle and liver (Fig. 7.5, 7.6, 7.7). When 4 hours 
were allowed between DOC administration and assay, a 
slight increase in GPx activity was observed in the 
tumour samples (Fig. 7.5) at all dose levels of DOC 
tested. This increase was not observed in the liver or 
the leg muscle. 
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Figure 7.5 Tumour glutathione peroxidase activity after DDC administration in 
BALB/c mice. Assays were performed 1 and 4 hours after DDC administration. 
Bars represent one standard deviation. 
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Muscle glutathione peroxidase activity after DOC administration in 
Assays were performed 1 and 4 hours after DOC administration. 
Bars represent one standard deviation. 
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Liver glutathione peroxidase activity after DOC administration in 
Assays were performed 1 and 4 hours after DOC administration. 
Bars represent one standard deviation. 
The changes in GPx activity after DDC administration 
observed here were found to be no different at the 5% 
significance level from saline treated mice using the 
Student's t-test. 
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Methods 
Catalase assay 
Most aerobic cells contain catalase (CAT). In mammals, 
catalase is present in all major organs, especially the 
liver and erythrocytes. Catalase was first isolated 
and obtained in crystalline form from ox liver by Sumner 
in 1941 . Most purified catalases have been shown to 
consist of 4 protein subunits, each of which contains a 
haem (Fe(III)-protoporphyrin) group bound to its active 
site. 
Catalase is responsible for the decomposition of hydrogen 
peroxide in cells by the following reaction. 
CAT 
This is a 2 stage reaction 
~~~-> compound 1 
The exact structure of compound 1 is uncertain, however 
the equations show that the complete removal of H2o2 
requires the impact of 2 molecules upon a single active 
site (Halliwell & Gutteridge, 1985). 
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The catalase activity may be measured by following either 
the decomposition of H2o2 or the liberation of o2 . The 
decomposition of H2o2 can be followed directly by the 
change in absorbance at 240 nm per unit time, which is a 
measure of catalase activity. 
The method of Holmes & Masters (1970), a modification of 
the original method of Beers & Sizer (1952), was used for 
catalase activity determination in this work. 
Preparation of tissue samples after 
intratumoural administration of DDC 
Male BALB/c mice were inoculated with a transplantable 
rhabdomyosarcoma in the right hind gastrocnemius muscle 
as described in Appendix 2. 
DOC solutions for intratumoural administration were 
prepared as described in Appendix 2. 
Four tumour bearing mice were used in each group. They 
were injected with 20 µl DOC intratumourally at a rate of 
0. 5, 50 and 250 mg/kg body weight. The control mouse 
was injected with 20 µl 0.9% saline. One or four hours 
after DOC administration, the mice were sacrificed and 
the tumour, liver and leg muscle were excised. These 
tissues were homogenised in a Potter-Elvehjem homogeniser 
in 2 ml 10 mM potassium phosphate buffer at pH 8.0 which 
was 30 mM in KCl. The supernatant, after centrifugation 
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for 20 minutes at 4°C at 17 210 X gin a Sorvall RC-SB 
centrifuge was used as the enzyme source in this assay. 
Measurement of catalase activity 
The reagents used are detailed in Appendix 1. 
The H2o2 concentration was kept low (10 mM) as the enzym
e 
is known to be inactivated by high concentrations of its 
substrate (Thomson, 1963). High concentrations of H2o2 
also lead to the formation of oxygen bubbles in the 
cuvette. 
The total reaction volume was 3 ml and consisted of 1.5 
ml tris hydroxymethylmethylamine, 1 .1 ml distilled water, 
0. 3 ml H2o2 and O. 1 ml tissue sample in a 3 cm
3 quartz 
glass spectrophotometer cuvette. Distilled water was 
substituted for the tissue sample in the reference 
cuvettes. 
Absorbance change at 240 nm was recorded using a Pye 
Unicam SP8-400 double beam spectrophotometer. Enzyme 
units were defined as the number of µmoles of H2o2 
converted per minute per mg protein, and were calculated 
on the basis of a molar absorption coefficient for H2o2 
at 240 nm of 43.6 M- 1 .s-1 (Holmes & Masters, 1970) as 
follows 
6 O.o. 240/min
 3 ml 1 
CAT Activity= --------------- X --------------- X -----------------------
0.0436 sample volume mg protein/ml of sample 
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Protein determination 
Protein was measured spectrophotometrically using a 
Pye-Unicam double beam spectrophotometer by the method of 
Lowry et al. (1951) 
Results 
Tumours used in this experiment ranged in size from 0.271 
to 1.416 cm3 with a mean volume of 0.663 cm3 ± 0.250 cm3 
(mean ± SD). Linear regression analysis was performed 
on the tumour size against CAT activity in saline treated 
(control) tumours, and a correlation co-efficient of 
r=0.6915 (p>0.1, 3 DF) obtained. No relationship 
between tumour size and tumour CAT activity could 
therefore be demonstrated. 
Tissue catalase activity 
Table 7. 3 shows that in saline treated (control) mice, 
CAT activity in the liver was about eight fold greater 
than in the tumour and twenty fold greater than in the 
leg muscle. 
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Tumour 0.825 ± 0.209 
Muscle 0.363 ± 0. 162 
Liver 6.291 ± 1 . 351 
95% confidence 
0.416 - 1 .235 
0.045 - 0.680 
3.644 - 8.938 
There did not appear to be any significant effect of DOC 
administration on the catalase activity in the tumour, 
leg muscle or liver (Fig. 7.8, 7.9, 7.10). Muscle 
catalase activity was slightly decreased after O. 5 and 
250 mg/kg DOC was injected 1 hour prior to assay, but the 
decrease was within the 95% confidence limits of control 
values (Fig. 7.9). The higher CAT activity observed at 
50 mg/kg DOC is probably artifactual since the standard 
deviation at this point is large. 
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Figure 7.8 Tumour catalase activity after DOC administration in BALB/c mice. 
Assays were performed 1 and 4 hours after DOC administration. Bars represent 
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Figure 7.9 Muscle catalase activity after DDC administration in BALB/c mice. 
Assays were performed l and 4 hours after DDC administration. Bars represent 
one standard deviation. 
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Figure 7. 10 Liver catalase activity after DDC administration in BALB/c mice. 
Assays were performed 1 and 4 hours after DDC administration. Bars represent 
one standard deviation. 
The changes in CAT activity after DOC administration 
observed here were found to be no different at the 5% 
significance level from saline treated mice using the 
Student's t-test. 
Discussion 
In 1978 Stone et al. showed in vitro that if DOC was 
removed from erythrocytes prior to irradiation, no effect 
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on sensitivity was seen. The authors concluded that 
this was due to insufficient SOD inhibition. 
The present work has shown that this is not necessarily 
so, as SOD inhibition can be maintained up to 24 hours 
after DDC treatment. This period is probably long 
enough for DDC in the tumour to have been completely 
metabolised. Indeed, 60% of DDC dose can be accounted for 
in excretory products after 3 hours following oral 
administration of DDC (Craven et al., 1976). 
Westman & Marklund (1980) demonstrated in vitro that SOD 
inhibition could be maintained in Chinese hamster cells 
after DDC was washed off the cells. These authors 
found that DDC caused a reduction in SOD activity to 
about 2% of control (no DDC) activities when SOD activity 
was assayed immediately after DDC incubation. Thirty 
minutes after this treatment, SOD activity was still only 
5% of the control, and after 24 hours was 10% of control 
activities. 
The work reported in this thesis on in vivo SOD activity 
in tumours after intratumoural DOC administration has 
shown similar results. DOC caused a marked inhibition 
of SOD soon after exposure (8% of control, hour after 
100 mg/kg DDC) which was sustained for up to 24 hours 
(Fig 7.3). 
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It is also of interest to note that when the DDC 
concentration was increased ( 150 mg/kg), a concomitant 
increase in SOD inhibition was not noted. In fact the 
higher concentration of DDC was less effective in 
inhibiting SOD. This 'biphasic concentration effect' 
has been shown for human lymphocytes, (where SOD was 
inhibited at only one of two toxic concentrations) (Rigas 
et al., 1979 ; Rigas et al., 1980), survival of Chinese 
hamster cells (Westman & Midander, 1984), survival of 
mouse fibroblasts (Maners et al., 1985) and enhancement 
of heat, radiation, bleomycin and adriamycin toxicity 
(Lin et al., 1985). 
In view of the fact that DDC has been shown to have both 
radiosensitizing (due to SOD inhibition) and 
radioprotecti ve properties, it is of interest to note 
that SOD inhibition can be maintained for some time after 
DDC administration both in vitro (Westman & Marklund, 
1980) and in vivo (Fig. 7.3) This is complicated by 
the concentration effects of DDC, but in principle, a 
situation could be reached where SOD activity is lowered 
in the cell, at the same time as free DDC levels are too 
low to be of any radioprotective consequence. 
There was no significant effect of DDC on catalase or 
glutathione peroxidase (Figs 7. 5 - 7. 10). This is in 
agreement with the findings of Marklund & Westman (1980) 
who found no or only insignificant effects of DDC on 
manganese-SOD, catalase, cytochrome oxidase and protein 
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sulphydryl levels as well as glutathione peroxidase 
(Westman & Marklund, 1983). 
There have been conflicting results in the literature as 
to the effect of DDC on glutathione peroxidase 
activities. A dose of 400 mg/kg DDC has been shown to 
cause an increase in mouse liver GPx after 2 hours (Weiss 
et al., 1985). DDC induced resistance to hyperoxia has 
been argued to be associated with an increased GPx 
activity (Deneke & Fanburg, 1980). A decreased GPx 
activity was reported in mouse lung and liver following a 
1.2 g/kg dose of DDC (Goldstein et al., 1979). However, 
it has been shown that DDC exhibits 'GPx-like' activity 
and could be substituted for GPx in the assay of Lawrence 
& Burk, (1976) When GPx was replaced by DDC, a 
concentration dependent 
(Kumar et al., 1986). 
enzyme-like activity was seen 





be a significant factor 
activity following DDC 
Conclusions 
There is a 90% decrease in SOD activity in DDC treated 
tumours. This decrease is maximal shortly after DDC 
administration, but SOD activity remains lowered up to 24 
hours after DDC administration. 
The implications of this are that a situation could arise 
where the DDC concentration in the tumours is not high 
enough to cause radioprotection (due to metabolism of 
DDC and the enzymatic defence against oxygen toxicity 703 
DOC), yet the SOD activity is low enough to allow 
radiosensitization. 
The inhibition of SOD is not necessarily linearly 
dependent on dose of DOC administered to the tumours. 
The observation that a higher dose of DOC resulted in a 
more modest decrease in SOD activity was not significant 
at the 5% level, however in view of the work of other 
investigators concerning a 'biphasic' concentration 
effect of DOC, this point deserves to be raised. 
No significant effect of DOC on catalase or glutathione 
peroxidase activity could be demonstrated. 
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Chapter 8 
Tumour growth delay 
The principles of the tumour growth delay assay, the 
tumour bed effect and the results of initial studies on 
in vivo DDC pretreatment are described in this chapter. 
Principles of the tumour growth delay assay 
The delay in tumour growth by treatment can be used as a 
measure of the effectiveness of the treatment 
(Thomlinson, 1980). The pattern of regression (if any) 
and subsequent regrowth is followed by making regular 
measurements of tumour size. The time taken for the 
treated tumours to reach a certain endpoint size is 
recorded and from this is subtracted the time taken for 
untreated tumours to reach that same size. 
One of the main problems in the interpretation of this 
data stems from the fact that the pattern of regrowth is 
usually different in treated and untreated tumours, 
making the choice of endpoint size at which to assess the 
delay critical in determining the magnitude of that 
delay. 
Mechanisms of damage that result in growth 
delay 
The growth retardation of tumours after radiation can 
result from either : 
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* damage to the stroma or vasculature (Tumour Bed 
Effect, TEE). 
* damage to tumour cells. 
It is perhaps pertinent to discuss the tumour bed effect 
at this point. 
The tumour bed effect 
It has long been known that tumour cells transplanted 
into pre-irradiated subcutaneous tissue take longer to 
establish tumours than cells transplanted into 
non-irradiated tissues, and that further growth of 
tumours in the irradiated tissue is reduced, for example 
(Vermund et al., 1956 ; Hewitt & Blake, 1968 ; Summers et 
al, 1964 ; Urano et al, 1980). This phenomenon is known 
as the Tumour Bed Effect or TEE and is thought to be due 
to the reduced ability of irradiated tissue to provide 
blood vessels to tumours. 
Normal tissue stroma that surrounds or infiltrates 
tumours plays a significant role in the growth and 
response of tumours to therapy. Tumour vasculature is 
formed by the stroma of the tumour bed in response to 
angiogenic factors released by the tumour cells (Folkman, 
1974). The formation of tumour blood vessels is usually 
inadequate to sustain tumour growth and leads to necrosis 













radiation. The inadequate blood supply to tumours may 
also compromise drug delivery (Steel & Adams, 1975). 
Pattern of growth retardation 
If the growth retardation results from stromal and not 
tumour cell damage, then it is feasible that some 
modifying agents may modify stromal damage to a greater 
degree than tumour cell damage. Begg (1980) has 
discussed this point, which is illustrated in Figure 8.1. 
CONTROL A C B 
ENDPOINT SIZE 
ENDPOINT SIZE 
DAYS AFTER TREATMENT 
Figure 8.1. Schematic growth curves for three different types of treatment A, 
B & C. A and B both produce equal cell killing, but B produces more stromal 
damage, hence treatment B results in slower tumour regrowth. C produces a 
greater amount of cell kill than A or B, but causes no stromal damage and 
results in the same growth delay as treatment B. Redrawn from Begg (1980). 
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Treatment A produces no stromal damage, thus after the 
initial tumour shrinkage due to the treatment, the tumour 
regrows at the same rate as the control. Treatment B 
however results in an equal amount of cell kill as 
treatment A, but in addition, causes some stromal damage, 
thus after the initial shrinkage, the tumour regrows at a 
slower rate than the control. Treatment Con the other 
hand results in more cell kill than treatment A or 
treatment B, but causes no stromal damage and regrows at 
the same rate as the control. 
The growth delay estimate would show treatment Bas being 
more effective than treatment A and equally effective as 
treatment C. If slower regrowth occurs as a result of 
stromal damage (B), the estimates of tumour growth delay 
should be based on the smallest possible endpoint size, 
for example marginally larger than the size at treatment, 
in order to avoid artificially large delays resulting 
from growth retardation. 
Choice of endpoint size 
The choice of endpoint size for this assay depends 
largely on the pattern of growth retardation. In many 
tumours the growth rate is initially slowed after 
treatment - which may be the result of slow clearance of 
cellular material (Begg, 1987), whereafter the growth 
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DAYS AFTER TREATMENT 
Fig 8.2. Representation of the effect of shrinkage on the shape of the 
regrowth curve. When no shrinkage occurs (A), the initial regrowth rate 
appears slower even if the proliferation rate of surviving cells remains 
unchanged. (Redrawn from Begg, 1980). 
If no tumour shrinkage occurs after treatment, the 
regrowth rate will be slow initially, giving the 
appearance of a tumour bed effect (Curve A in Fig 8.2). 
This is because the influence of a large non-growing mass 
may considerably slow the observed tumour growth rate. 
In this case, the choice of a small endpoint size will 
lead to an incorrect low estimate of growth delay. In 
this case an endpoint size should be chosen large enough 
not to cause the growth delay estimate to occur in this 
artificially slow growth period. If shrinkage occurs, 
(Curve B in Fig 8.2), the influence of this non-growing 











mass diminishes, and the tumour as a whole rapidly 
attains the growth rate of the surviving cells. Here an 
endpoint size should be as low as possible so as not to 
allow the estimate to be influenced by changes in growth 
rate due to the TEE as well as increasing necrosis and 
hypoxia with increasing size (Hill, 1980). 
A third possibility is shown in Figure 8. 3, where the 
data can only be fitted assuming a changed proliferation 
rate of surviving cells due to the tumour bed effect. 




DAYS AFTER TREATMENT 
Fig. 8.3. In this growth curve, the lack of shrinkage cannot account for 
growth retardation, and a changed proliferation rate of surviving cells is 
indicated. 
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Thus, because tumours show different growth patterns of 
regrowth, it is important to measure tumour size 
regularly. 
Tumour size at treatment 
Tumour size at treatment is important as blood supply 
deteriorates and resistance to radiation and drugs 
increases with increasing tumour size (Stanley et al., 
1979). As a consequence, for an equal amount of cell 
kill; large, more slowly growing tumours will produce a 
bigger estimate of growth delay than small, faster 
growing tumours. (Begg, 1980). 
It is therefore important to treat tumours that fall 
within a narrow size range in order to minimise the 
variability of the results. 
Initial studies on tumour growth delay 
The results presented here are those of exploratory 
studies used in the formulation of the hypothesis 
outlined in chapter 6. At the stage that these 
experiments were performed, it was believed that DOC 
pretreatment could result in a significant decrease of 
SOD (as shown in chapter 7) and that this could result in 
sensitization to ionizing radiation, but it was not known 
to what extent the radioprotective properties of DDC 
would influence this sensitization. 
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Objectives 
* To examine the effect of a time delay of 1 - 24 
hours between DDC pretreatment and irradiation on 
tumour growth in a murine rhabdomyosarcoma 
* To calculate tumour growth delay times in these 
mice. 
Methods 
Male BALB/c mice bearing a 3-methylcholanthrene induced 
rhabdomyosarcoma were used. The mice and tumours were 
maintained as described in Appendix 2. 
X-irradiation 
Tumour bearing mice were restrained on an acrylic plastic 
jig and immobilised with elastic bands as shown in Fig. 
8.4. The mice were briefly anaesthetised in ether prior 
to immobilisation. A Philips RT 100 medium voltage 
X-ray unit was used for the X-irradiations, operating at 
100 kVp and 8 mA, with an HVL of 3 mm Al giving a dose 
rate of from 7.93 to 8.04 Gy/min at the centre of the 
field. A 2. 5 cm diameter circular applicator with an 
SSD of 10 cm was used and placed directly above the 
tumour. 
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Figure 8.4 The irradiation setup for X-irradiations. A 2.5 cm diameter 
circular applicator with an SSD of 10 cm was used and placed directly above the 
tumour. 
The X-ray unit was calibrated with a flat (small volume -
0.3 cm3 ) ionization chamber connected to a Baldwin Farmer 
secondary standard dosimeter, and placed at the end of 
the 2.5 cm diameter circular applicator with an SSD of 10 
cm. The dose rate at this distance in the centre of the 
field was measured to be 7.36 Gy/min when the output of 
the machine was 65 Roentgens/min, measured at 30 cm with 
a standard 5 cm diameter circular applicator. The 
output of the machine was measured weekly, and 
corrections were made for changes in output in the 
calculation of dose rate. 
was 11 Gy - 18 Gy. 
The X-ray dose to the tumours 
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60 Cobalt gamma irradiation 
Tumour bearing mice were restrained in acrylic plastic 
jigs as shown in Fig 8. 5. The mice, apart from the 
tumour-bearing legs were shielded with 1 0 cm thick lead 
blocks. 0.5 cm thick acrylic plastic strips placed over 
the tumours were used as build-up. The mice were 
briefly anaesthetised in ether prior to immobilisation. 
Irradiation was performed using an Eldorado 6 60co 
source, with a fixed cast lead collimator. 
Figure 8.5 The irra~iation setup for irradiation using the Eldorado 6 Cobalt 
Unit. 
The dose rate was measured with a O. 5 cm3 ionization 
chamber connected to a Baldwin Farmer secondary standard 
dosimeter, at 80 cm from the source in a 40 X 40 cm field 
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with full secondary electron build-up and backscatter 
provided by 40 cm of wood. The dose rate was O. 516 
Gy/min in June 1987, which increased to 0.821 Gy/min in 
October 198 7 as a result of a source change, and was 
0.579 Gy/min in June 1990. 
In order to calibrate the Eldorado 6 for irradiation of 
the mouse tumours using the geometric arrangement 
described above, the 0.5 cm3 ionization chamber was 
placed in the position of the tumour and the dose 
measured. 
Neutron irradiation 
BALB/c mice were inoculated with a 3-methylcholanthrene 
induced rhabdomyosarcoma in the same way as for the X-ray 
experiments . They were briefly anaesthetised in ether 
before being gently restrained in an acrylic plastic jig 
with elastic bands as shown in Fig. 8.6. Neutron 
irradiations were performed using the p ( 66) /Be ( 40) 
neutron therapy isocentric unit of the National 
Accelerator centre in Faure, South Africa. 
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Figure 8.6 The irradiation setup for irradiation using the Faure neutron 
therapy beam. 
A 20 X 20 cm field was used, and the mice were positioned 
such that only the tumour bearing leg was within the 
field. The jig was placed on 9 cm of acrylic plastic 
which provided backscatter, and a 20 X 20 X 2 cm closed 
plastic box containing a tissue equivalent solution 
(containing 65.6% H2o, 26.8% glycerol and 7.6% urea 
( Goodman, 1969)) placed above the tumours served as 
buildup. An SSD of 150 cm was used. Total dose 
(neutron + gamma) at the position of the tumours was 
kindly determined by Dr D.T.L. Jones, using the 
international protocol for neutron dosimetry (Mijnheer et 
al., 1987). The dose to the tumours was 7 Gy and 9 - 10 
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mice were used in each treatment group. Assessment of 
tumour growth delay was done in the same manner as for 
the X-ray experiments. 
Assessment of response 
Tumour growth delay was assessed by measuring the 3 
orthogonal diameters, using vernier calipers, of each 
tumour 3 times per week. The volume of the tumour 
was calculated assuming a spherical shape by the 
relationship: 
V = 4/3 nr3 
(a+ b + c) 
where r = X 
3 2 
and a, band care the orthogonal tumour diameters, until 
a volume of 0.6 cm3 was obtained, at which point the mice 
were sacrificed . 
Tumour volume at the time of treatment ranged from 0.155 
to 0.333 cm3 with a mean of 0.219 cm
3 ± 0.038 cm3 (mean± 
SD) Some tumours did not grow in the normal oblate 
spheroid shape, but in a multilobed or sausage shape. 
Such irregular shaped tumours were not used in the 
estimation . 
Validation of tumour volume measurement 
In order to validate the method used to assess tumour 
response, certain tumours were measured more than once 
Tumour growth delay 
during a measurement session. 
tendency were then calculated. 
777 
Measures of central 
Table 8. 1 below shows that during repeated measurements 
of the same tumour, the standard deviation was usually 
around 10% of the mean volume. 
Table 8.1 Validation of tumour measurement. 
Mouse mean tumour SD coefficient number of 
number volume (cm3) of variation measurements 
B4 0.453 0.043 9.5% 14 
C2 0.359 0.043 11 . 9% 4 
F3 0.352 0.033 9.4% 4 
A1 0.270 0.021 7.7% 4 
D4 0.300 0.025 8.4% 4 
H3 0.360 0.037 10.4% 4 
Results and discussion 
Growth delay times after DDC pretreatment 
Tables 8.2 to 8.4 show the median growth times*, tumour 
volume doubling times and tumour starting sizes after 
pretreatment with DDC prior to X-irradiation. 
* median of the times taken for a tumour to reach O. 6 
cm3 . 
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Table 8.2 Median growth time, volume doubling time and tumour starting sizes 
for mice treated with 50 mg/kg DOC intratumourally, followed by a time delay of 
1 to 24 hours prior to an 11 Gy X-ray dose. 
Treatment 
None 
11 Gy only 
DOC + 11 Gy 
DOC+ 11 Gy 
DOC+ 11 Gy 
DOC + 11 Gy 
DOC+ 11 Gy 
DOC + 11 Gy 
Time 
between DOC 
number Growth Doubling Cures Initial Tumour 
of Time Time Volume (cm3) 







































0.255 t 0.044 
0.208 :! 0.016 
0.190 !: 0.036 
0.198 ! 0.010 
0.219 :l: 0.034 
0.198 !: 0.028 
0.200 :!: 0.020 
0.214 ~ 0.035 
Table 8.3 Median growth time, volume doubling time and tumour starting sizes 
for mice treated with 100 mg/kg DOC intratumourally, followed by a time delay 
of 1 to 24 hours prior to an 11 Gy X-ray dose. 
Treatment 
None 
11 Gy only 
DOC only 
DOC + 11 Gy 
DOC + 11 Gy 
DOC + 11 Gy 
DOC + 11 Gy 
DOC+ 11 Gy 
DOC+ 11 Gy 
Time 
between DOC 
number Growth Doubling Cures Initial Tumour 
of Time Time Volume (cm3) 











































0.255 :!: 0.044 
0.208 ! 0.016 
0.191 ! 0.015 
0.231 ! 0.020 
0.232 t 0.033 
0.219 = 0.026 
0.209 '!. 0.037 
0.229 ! 0.038 
0.190 ± 0.030 
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Table 8.4 Median growth time, volume doubling time and tumour starting sizes 
for mice treated with 150 mg/kg DDC intratumourally, followed by a time delay 
of 1 to 24 hours prior to an 11 Gy X-ray dose. 
Treatment 
None 
11 Gy only 
DDC + 11 Gy 
DDC + 11 Gy 
DDC + 11 Gy 
DDC + 11 Gy 
DDC + 11 Gy 
DDC + 11 Gy 
Time 
between DDC 
number Growth Doubling 
of Time Time 
and radiation mice (days) (days) 
15 6.2 4.0 
8 12.4 9.3 
1 hour 4 15. 9 10.4 
2 hours 4 10.4 7. 1 
4 hours 12 12.6 11. 6 
6 hours 4 13.8 9.5 
12 hours 4 13.4 10.3 
24 hours 4 6.6 4.0 
When these results were first 




0 0.208 i 0.016 
0.191 ! 0.027 
1 0. 188 i 0.025 
3 0. 249 ! 0. 055 
1 0.235 ! 0.039 
1 0.235 :t 0.040 
0 0.231 t 0.036 
reported (Kent & 
Blekkenhorst, 1988), the mean growth times and growth 
delays were calculated; however in some of the treatment 
groups, tumour cures were noted and no estimate of growth 
delay could be calculated. This led to the unfortunate 
situation where for treatments within the range of 
curability, growth delay estimates could only be 
calculated for those tumours which recurred ; i.e. the 
subgroup least affected by the treatment. The subgroup 
that was most affected by the treatment (cured tumours) 
did not recur, and therefore provided no data for 
calculation of growth delay. This kind of problem and 
the need for a statistical solution have been discussed 
previously (Wheldon & Brunton, 1982). 
In Tables 8. 2 to 8. 4, the median growth time is used 
rather than the mean as the median growth time can 
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accommodate cured tumours (as long as they do not 
comprise more than 50% of the group) and thus allow 
comparisons to be made between treatment groups. Where 
no cures were noted mean growth times could be compared 
for significant differences using the Student's t-test. 
The growth 
pretreatment 
times of tumours 







irradiation were compared to the growth times of tumours 
receiving radiation only using a Student's t-test, 
however these differences were not significant at the 5% 
probability level. When the DDC dose was increased, 
( Tables 8. 3 8. 4) some tumour cures are noted making 
comparisons of mean tumour growth time or volume doubling 
time impossible. 
Al though it is not possible to base any conclusions on 
these results, as no significant differences could be 
detected between treatment groups, it is clear that DDC 
has the ability to help cure some of these tumours in 
certain circumstances, thus some discussion is warranted. 
When the time delay between DDC administration and 
X-irradiation was short, for example 1 hour, pretreatment 
with 50 or 100 mg/kg DDC resulted in a slight shortening 
of the tumour growth time when compared to those tumours 
treated with radiation only. When this time delay was 
increased to 4 hours, the growth times increased and 
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cures were noted at 100 mg/kg indicating that tumour 
sensitization took place. 
Treatment with 100 mg/kg DDC 4 or 6 hours prior to 
irradiation resulted in 4 out of 12 tumours regressing 
completely. The tumour doubling times also followed a 
similar pattern. The doubling time was reduced when a 
50 mg/kg DDC dose was administered hour prior to 
irradiation, but was not affected by a higher 100 mg/kg 
DDC dose when comparison was made with radiation only. 
The increase in tumour growth time after a 4 to 6 hour 
delay between 50 mg/kg DDC and irradiation was not 
reflected in the volume doubling time, but was shown when 
the DDC dose was increased to 100 mg/kg. 
The starting tumour volumes in these groups were 
comparable, and should not have affected their response. 
The result of increasing the DDC dose to 150 mg/kg was 
that about 25% of the tumours were cured when the delay 
between DDC administration and irradiation was to 12 
hours (Table 8.4). 
Systemic administration of DDC 
It was felt that it would be important to determine if 
systemic administration of DDC could also affect the 
tumour response. 
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The tumours used in this later experiment were found to 
be more radioresistant than those used in the earlier 
experiments with intratumoural administration of DDC. 
For this reason a higher dose of radiation, 18 Gy was 
chosen. 
Table 8.5 shows that when DDC was injected 
intraperi toneally hour prior to irradiation, tumours 
grew to 0.6 cm3 4.5 days faster than tumours treated with 
X-rays alone. When a longer delay was allowed between 
DDC administration and irradiation, a tumour growth delay 
of 2.9 days was seen when 2 hours was allowed between DDC 
pretreatment and irradiation. It is probable that a 
dose of 100 mg/kg DDC injected systemically resulted in 
lower DOC concentrations than when DOC was injected 
intratumourally. For this reason a dose of 1000 mg/kg 
DDC was given which resulted in out of 5 tumours 
regressing. 
None of these differences were significant at the 5% 
level (Comparison of mean growth times 
t-test). 
Student's 
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Table 8.5 Tumour growth time and cures in BALB/c mice after systemic DDC 
pretreatment and radiation. 
Treatment 
18 Gy only 
100 mg/kg DDC hr before 18 
100 mg/kg DDC 2 hr before 18 




Days to 0.6 cm3 
(mean± SD) 
16.9 ± 3.2 
12.3 ± 0.5 
19.8 ± 1 . 8 
15.8 ± 1. 3 








Table 8.6 shows that tumours treated with DOC and 
neutrons grew faster than those treated with neutrons 
alone. The mean growth time of tumours treated with 100 
mg/kg DDC 1 hour prior to 7 Gy neutrons was found to be 
significantly different from the mean growth time of 
tumours treated with neutrons alone (p<0.05). There was 
no difference in the growth time of tumours treated with 
DDC 1 or 4 hours prior to irradiation. 
Table 8.6 Tumour growth times for BALB/c mice treated with neutrons with and 
without prior treatment with DDC. t - values, read at 17 degrees of freedom 
are for comparisons of DDC treatments with neutron only treatments. N.S. = not 
significant. 
Treatment 3 Days to reach 0.6 cm 
7 Gy neutrons only 
100 mg/kg DDC 1 hr before 7 Gy neutrons 
100 mg/kg DOC 4 hr before 7 Gy neutrons 
mean "t SD ( n=9) 
12.8 :! 0.9 
10.2 i 0.8 
10.1 '! 0.9 
significance 
t = 2. 147 
t = 2.009 
p<O. 05 
N.S. 
724 Chapter 8 
The protection factor (PF 1. 3) shown by DDC 
pretreatment hour prior to neutron irradiation is 
interesting as it has been previously demonstrated that 
chemical radioprotectors are more efficient at protecting 
tissues from low LET radiation than high LET radiation 
(Sigdestad et al., 1975 ; Sigdestad et al., 1976). 
Sigdestad et al. (1986) gave as possible reasons for the 
difference the following points : 
a) The influence of free radical scavenging and/or 
hydrogen ion donation would be greater in low LET 
because of (i) the degree to which radiolysis of 
water affects cell killing by radiations of 
different qualities, and (ii) LET differences in 
the subcellular dose distribution. 
b} The induction of hypoxia by the radioprotector 
(see chapter 5) would be expected to increase 
survival to a greater extent after low LET, 
because of the greater oxygen effect on low LET 
radiation injury. 
It is important to note that the Faure neutron beam has a 
small gamma component which is highest at the edge of the 
field ( Yudelev & Jones, 1988) , where the tumours were 
situated for the irradiations. 
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Problems of tumour growth delay studies 
Already at this point in the study, some of the 
limitations of the growth delay assay became apparent. 
Some of the growth delay times were 'censored'. i.e. the 
mice never reached the endpoint in question ( 0. 6 cm3 
tumour volume in our case), because their tumours were 
'cured'. This kind of experiment where tumours are 
measured after subcurative therapy is also prone to loss 
of data from other sources such as premature death (death 
before the endpoint is reached) due to metastasis or 
intercurrent disease. 
It must be pointed out at this stage that growth delay 
assays are very frequently used to quantify tumour 
response to radiation or some other cytotoxic treatment 
modality, but that volume changes do not necessarily 
mirror the effect of the treatment on tumour cell 
survival (Jung et al., 1981). Indeed, the volume 
changes may depend on not only the surviving tumour 
cells, but also on factors such as the rate at which the 
tumours are repopulated by the surviving cells, the rate 
of resorption of radiation-sterilised cells, the necrotic 
portion of the tumour, and also on the numbers of host 
cells migrating into the tumour. 
Nevertheless, the tumour growth delay is a very useful 
method of assessing the response of experimental tumours 
to radiation and cytotoxic treatment. The assay 
726 Chapter 8 
requires fewer animals than 50% tumour control dose 
studies (TCD 50 ) and is therefore 
more economical. 
Denekamp ( 1979, 1980) reviewed the different assays 
available for measuring the response of tumours in situ 
to therapy, namely animal survival time, regression rate 
of tumours, regrowth delay, local tumour control, and 
loss of incorporated radioactivity. It was argued that 
any single assay was adequate, provided a dose response 
relationship could be demonstrated. Survival time and 
regression rate studies probably yielded the least 
valuable information, but the tumour growth delay assay 
appeared to be more closely dependent on cell survival. 
The tumour growth delay assay has been shown to yield 
well defined dose response curves after localised 
treatment, (for example Thomlinson & Cradock (1967), 
Field et al., (1968), Denekamp & Harris (1975)). 
In dealing with data 





approaches. Williams et al., ( 1984) either excluded 
animals from his analysis, or time of death was taken as 
the minimum regrowth time, but only if it was longer than 
the mean of that dose group. 
Suit et al., ( 1978) on the other hand argued that the 
allotment of some arbitrary value to a cured tumour had 
no sound theoretical basis. 
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Robinson et al., (1974) used the slope of the regrowth 
curve as a measure of effectiveness of treatment, rather 
than the delay to reach a certain size. 
Sheldon & Smith ( 1975) plotted the mean reciprocals of 
the growth delay time, regarding controlled tumours to 
take 'infinite time' to grow to the particular endpoint. 
Nowak et al., (1978) used the median doubling time of 
each treatment group to assess the response of treatment. 
Some tumours that failed to regrow and therefore had 
infinitely large doubling times were not a problem, 
because unless more than half the tumours in a particular 
group fail to regrow, the median is a parameter that 
allows these animals to remain part of the analysis. 
Fowler et al., (1980) have analysed tumour local control 






by regarding the tumour growth delay as infinite, 
and using reciprocals of growth time to obtain an 
average. 
by allocating some arbitrary growth time - 150, 
300 or 1000 days. 
by using the lifespan of the mouse. 
by using the latest time at which a recurrence has 
ever been observed. 
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Fowler et al., (1980) examined experiments where both a 
tumour growth delay and a tumour control ( TCD50 ) assay 
had been performed to determine enhancement ratios for 
some adjuvant treatments. They found that agreement 
between enhancement ratio estimates derived from the 
regrowth results and tumour cure (TCD 50 ) results 
was good 
when these methods were used to handle cured tumours in 
several experimental situations. When cured tumours 
were merely ignored, this agreement between tumour growth 
delay assays and TCD 50 assays was poor. 
Assessment of tumour response using the 
Kaplan-Meier method 
It was realised in the early stages of the investigations 
reported in this thesis that the use of any of the 
methods for growth delay described above was not 
adequate. It was thus concluded that the best way of 
dealing with censored growth delay data was to make use 
of the method proposed by Kaplan & Meier (1958). This 
method allowed the inclusion of growth delay data for 
tumours both from animals in which tumours were cured, 
and for tumours lost due to death from intercurrent 
disease before the endpoint was reached. 
This method has been used for some time in clinical 
trials to estimate survival after different treatments. 
The prognosis of patients with cancer is often described 
by a single figure such as 5 year survival, but only the 
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survival curve shows the complete time course of the 
disease. The curve shows the probability at different 
times of survival. The methods used in constructing a 
survival curve can be used to analyse the time taken to 
reach any event. Indeed the term 'survival curve' used 
in the context of the Kaplan-Meier model is merely a less 
clumsy way of saying 'the probability at successive times 
that an event has not occurred (Peto, 1984). 
The calculation of a survival curve requires only two 
parameters, namely : 
1) a response variable This is essentially a 
logical yes/ no variable. - (Did the patient die 
?) • 
2) a time variable : This is the time taken to reach 
the particular response in question. For 
example, if the patient died - how long after the 
start of treatment did he/she survive? If the 
patient is still alive / lost to follow up - How 
long has that patient survived? 
There was thus no reason why a survival curve could not 
be constructed for the data presented in this thesis, 
using the time for the tumour to grow to a certain 
endpoint size as the time variable, and the achievement 
of the endpoint size or not as the response variable. 
This method has been called many names in clinical 
studies, 'actuarial curve', 'product-limit curve', 
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'Kaplan-Meier curve', or simply the survival curve. A 
modified, but essentially identical method, where data is 
grouped into weeks, months or years is known as the 'Life 
Table' method (Sylvester et al., 1978). 
Comparison of survival curves 
In a review of 
Breslow ( 1984) 
tests 
argues 
for comparing survival curves, 
that the standard test for 
comparison of survival curves is the Mantel-Haenzel or 
logrank test (Mantel & Haenzel, 1959), (Mantel, 1966). 
That the Kaplan-Meier method used in the analysis of 
tumour growth delay data in this thesis was a suitable 
method, was underscored by the recent publication of a 
paper by Stuschke et al., ( 1990). The authors used 
computer simulations to test the appropriateness of the 
method in situations where censored data was present. 
They argued that omission of censored growth delay data 
often leads to biased estimates. They found that the 
power of the logrank test and the conventional t-tests 
were about the same when comparing uncensored data from 
two therapy groups. The tests applicable to censored 
data ( logrank) had a markedly higher power than tests 
applied to a reduced set of complete observed growth 
delay (Student's t-test, Mann-Whitney u-test). They 
asserted that the Kaplan-Meier method is suitable for 
quantitative and qualitative analysis of growth delay 
data up to a censoring rate of 30%. 
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In view of the fact that this approach to growth delay is 
somewhat novel, details of the method of calculating a 
survival curve are presented in Appendix 5. 
Conclusions 
A time dependent modulation effect of DDC was observed, 
after both intratumoural · and systemic administration of 
DDC. It appeared that a greater degree of 
sensitization could be achieved if a time lapse was 
allowed between DDC administration and radiation. This 
sensitization could be masked by a radioprotective effect 
if the time lapse was short. 
The evidence provided here is not yet adequate to 
characterise the fine balance between the radioprotective 
and radiosensitizing action of DDC, nor to determine the 
concentration and time dependence of these effects. 
The presence of 'censored' data made these effects of DDC 
difficult to describe statistically. 
The methods used for analysis of tumour growth delay data 
were inadequate. The Kaplan-Meier method is suggested 
as an appropriate alternative. 
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A prospective randomised trial in 
tumour-bearing mice of irradiation with 
and without prior treatment with DDC 
In the previous chapter it was suggested that a 4 hour 
time delay between DDC administration and irradiation 
could possibly result in tumour sensitization, and that 
if this time delay was short, for example 1 hour, the 
sensitization could be masked by a radioprotective 
effect. 
In order to confirm the results presented in the previous 
chapter, it was decided to repeat the experiments; but 
with a change in the methods to limit the possibility of 
bias in the measurement of tumours and interpretation of 
results. This was achieved by randomisation and in the 
way in which data was collected. 
Two prospective randomised trials are described where 
tumour bearing mice were allocated to either : 
* DOC pretreatment 
irradiation. 
or 4 hours prior to 
* Saline placebo pretreatment 1 or 4 hours prior to 
irradiation. 
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Methods 
Experimental animals and tumours 
Female BALB/c mice bearing a 3-methylcholanthrene induced 
rhabdomyosarcoma were used. 
The tumours were maintained by serial passage of tumour 
from an original group that was inoculated with 3-
methylcholanthrene (Appendix 2). As the tumours used in 
this experiment were derived from different original 
stock, it was found that they were faster growing and 
more radioresistant than those used in the initial 
experiments described in chapter 8. 
of the protocol is given below. 
A brief description 
Eligibility and exclusion criteria 
8 to 12 week old female BALE/ c mice bearing a 
3-methylcholanthrene induced rhabdomyosarcoma in the 
right hind gastrocnemius muscle with a volume of between 
0.170 and 0.300 cm3 were considered eligible for the 
trial. 
Mice were excluded from the trial if a) the tumour was 
not approximately spherical in shape, and b) the tumour 
was situated on the upper part of the thigh such that it 
was not possible to position the entire observable tumour 
within the radiation field. 
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Stratification and randomisation 
A stratified randomisation was performed. The volume of 
each tumour was calculated as described in chapter 8, and 
the mice divided into two strata, those bearing small 
tumours (0.17 - 0.23 cm3 ) and those bearing large tumours 
(0.231 
separately. 
The strata were randomised 
This ensured that the same number of mice 
bearing small and large tumours fell into the different 
treatment arms. 
Randomisation was performed so that a similar number of 
mice fell into each treatment group. This was done by 
generating the numbers 1 to 12 in random order by means 
* of a random number generator These numbers were then 
sequentially drawn, and the treatment allocated in the 
following way : 
No's 1 - 3 Treatment A 
No's 4 - 6 Treatment B 
No's 7 - 9 Treatment C 
No's 10 - 12: Treatment D 
DDC pretreatment 1 hour prior to radiation 
DDC pretreatment 4 hours prior to radiation 
saline pretreatment 1 hour prior to radiation 
saline pretreatment 4 hours prior to radiation 
This meant that for every twelve mice entered into a 
stratum, 3 were allocated to each treatment group. 
Treatment 
A solution of DDC was prepared in O. 9% saline such that 
20 µl could be injected at a dose of 100 mg/kg body 
* Turbo Pascal Ver.4.0 (Borland) 
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weight. In the placebo arms, 20 µl saline was injected 
into the tumours. 
The mice were immobilised and the tumours irradiated with 
gamma rays from an Eldorado 6 60co unit as described in 
Chapter 8. 
single dose. 
dose of 25 Gy. 
The dose to the tumours was 11 Gy in a 
The trial was later repeated with a tumour 
Data collection and analysis 
Once a mouse was randomised, it was allocated an identity 
number, which was marked on the tail. A record of each 
mouse's treatment allocation was kept with this identity 
number. 
No record of the mouse's treatment group was ever kept 
with the data retrieval forms, or on the cages. Mice 
from different treatment groups also shared the same 
cage. This meant that during the routine measurement of 
the mouse tumours, the treatment group was unknown to the 
investigator. This was done to make the assessment of 
tumour response as 'blind' as possible. 
Tumours were measured three times per week and the volume 
calculated as described in Chapter 8. The tumours were 
measured until a volume of 0.6 cm3 was reached, whereupon 
the mice were sacrificed by prolonged exposure to ether. 


















the number of days after treatment. 















--8- Control + 25 Gy -0-- 11 Gy 
0.000 
0 2 4 6 8 
+ 
10 
DAYS AFTER TREATMENT 
Chapter 9 
This data is 
+ 
12 14 
Figure 9.1 Mean tumour volume following no treatment (solid li
ne), 11 Gy 
(dashed line) and 25 Gy (dotted line). Each point is the mean 
of between 10 
and 30 determinations. Uncertainty bars have been omitted to p
reserve 
clarity. 
Fig. 9.1 shows that no shrinkage was observed follow
ing 
treatment. After 25 Gy, the tumour growth rat
e was 
initially slowed, before regrowth at a slower rate t
han 
the control, suggesting the possibility of a stro
mal 
damage in addition to tumour cell kill (see chapter 
8). 
The response after 11 Gy was similar to that after 25 
Gy, 
except that the initial slower growth rate was 
of 
Randomised Trials 737 
considerably shorter duration. Based on this graph, it 
was felt that an endpoint size of 0.6 cm3 was justified. 
Tumour regression or 'cure' was defined as the absence of 
any palpable tumour for a period of at least 30 days, 
whereupon the mouse was sacrificed. 
Results 
Comparison of placebo arms 
On comparison of the two placebo arms where 20 µl of 0.9% 
saline was injected either 1 or 4 hours intratumourally 
prior to irradiation with 11 Gy gamma rays, no difference 
in the response of these 2 groups was discernable in 
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Figure 9.2. Response curves of the two placebo arms. 
(solid line) n=23, large stratum Rx: 20 ....J saline 1 hr before 11 Gy. 
(dotted line) n=21, large stratum Rx: 20 ,;J saline 4 hr before 11 Gy. 
A response was defined as the tumour reaching a volume of 0.6 cm
3 • 
The Kaplan-Meier median growth times (see Appendix 5) of 
the placebo arms are presented in Table 9.1. 
Table 9.1 
Gy. 
Kaplan-Meier median growth times after placebo treatment and 11 
Treatment arm 
20 .uJ saline 1 hr before 11 Gy 
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As the Kaplan-Meier curves were so similar for the two 
placebo groups it was decided to analyse their mean 
growth times. As there were no 'censored' data points, 
this kind of analysis was possible. A Student's t-test 
was performed, and at value of 0.176 was obtained. This 
indicated that there was no significant difference 
between these two groups as expected, thus these 2 
treatment arms were combined for any further comparisons. 
Comparison of DDC arms 
Fig. 9. 3 shows that there was a significant difference 
between the DDC groups in the large tumour stratum where 
the growth time after a DDC pretreatment 4 hours prior to 
irradiation was increased significantly (Chi square= 
4. 93, 0. 05>p>0.01, logrank test) when compared to a DDC 
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Response curves of the two DOC arms of the large tumour strata. 
n=21, large stratum Rx 100 mg/kg DOC 1 hr before 11 Gy. 
n=21, large stratum Rx: 100 mg/kg DOC 4 hr before 11 Gy. 
(dashed line) n=44, large stratum Rx: 20 .u) saline before 11 G~. 
A response was defined as the tumour reaching a volume of 0.6 cm. 
7 
Table 9. 2 Shows the Kaplan Meier median growth times of 
these 3 groups. 
In addition, on comparison of the mean growth times of 
the two DDC arms, a significant difference was found 
using the Student's t-test (t=2.519, 40 DF, p<0.02). No 
tumour cures were noted. 
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Table 9.2 Kaplan-Meier median growth times after DOC pretreatment and 11 Gy 
for the large tumour and small tumour strata. 
LARGE STRATUM SMALL STRATUM 
Treatment arm number median number median 
747 
growth time growth time 
20 .uJ sa l i ne before 11 Gy 44 3.6 days 33 4.6 days 
100 mg/kg DOC 1 hr before 11 Gy 21 3.2 days 18 5.0 days 
100 mg/ kg DOC 4 hr before 11 Gy 21 4.2 days 16 4.9 days 
There was no significant difference between the mean 
growth times, using a Student's t-test, of the two large 
tumour DDC strata and the saline controls. The 
difference in mean growth time between DDC pretreatment 4 
hours prior to irradiation and the saline control was 
however, close to the 5% significance level (t=1.956, 63 
DF 0.1> p >0.05). 
There was no measurable difference in the response curves 
of the DDC groups and saline controls in the small tumour 
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Response curves of the two DDC arms of the small tumour strata. 
n=18, small stratum Rx 100 mg/kg DDC 1 hr before 11 Gy. 
n=l6, small stratum Rx: 100 mg/kg DDC 4 hours before 11 Gy. 
(dashed line) n=33, small stratum Rx: 20 .AiJ saline before 11 G~. 
A response was defined as the tumour reaching a volume of 0.6 cm. 
The observation that DDC administration affected the 
radiation response of larger, but not smaller tumours was 
unexpected. Therefore the trial was repeated with a 
higher radiation dose to check if this effect could be 
replicated. 
As was seen with the 11 Gy trial, no difference between 
the DDC arms was observed in the small tumour stratum 
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(Fig. 9.5). In the large tumour stratum however, a 
significant difference (Chi-square = 4.21 0.05> p 
> 0.01 , logrank test) was again seen between the two DOC 
arms (Fig. 9.6). 
The Kaplan-Meier median growth times for the large and 
small tumour strata after 25 Gy are presented in Table 
9.3. 
Table 9.3 Kaplan-Meier median growth times after DDC pretreatment and 25 Gy 
for the large tumour and small tumour strata. 
LARGE STRATUM SMALL STRATUM 
Treatment arm number median number median 
growth time growth time 
20 ,ul saline before 25 Gy 10 11. 5 days 16 12.0 days 
100 mg/kg DDC 1 hr before 25 Gy 10 9.9 days 16 12.4 days 
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Figure 9.5 Response curves of the two DDC arms of the small tumour 
strata 
after DDC pretreatment and 25 Gy. 
(solid line) n=16, small stratum Rx 100 mg/kg DDC 1 hr before 25 Gy. 
(dotted line) n=15, small stratum Rx 100 mg/kg DDC 4 hr before 25 Gy. 
(dashed line) n=16, small stratum Rx : 20 .Ml saline before 25 G~. 
A response was defined as the tumour reaching a volume of 0.6 cm. 
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Figure 9.6 Response curves of the two DDC arms of the large tumour strata 
after DDC pretreatment and 25 Gy. 
(solid line) n=lO, large stratum Rx 100 mg/kg DDC 1 hr before 25 Gy. 
(dotted line) n=lO, large stratum Rx 100 mg/kg DDC 4 hr before 25 Gy. 
(dashed line) n=lO, large stratum Rx: 20 »J saline before 25 G~. 
A response was defined as the tumour reaching a volume of 0.6 cm. 
Discussion 
The results presented here confirm the hypothesis 
presented in chapter 6 that DOC could modulate the 
effects of radiation injury depending on the time lapse 
between DOC administration and irradiation. It appeared 
that in larger tumours (0.230 - 0.300 cm3 ) DOC sensitized 
the tumours to radiation when the time between DOC 
746 
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administration and radiation was four hours, whereas w
hen 
this time delay was only one hour, the sensitizat
ion 
appeared to be masked by a radioprotective effect. 
The radioprotective effect was most likely a reflect
ion 
of higher tumour DDC concentrations at the time 
of 
irradiation when the time delay was only hour, e
ven 
though SOD activity was greatly inhibited. When 
the 
time delay was increased to 4 hours, the tumour 
DDC 
concentration was probably less than at 1 hour, and t
his 
allowed the lowered SOD activity to take the domin
ant 
role in modifying the response to radiation. 
The fact that this time modulation effect of DDC was 
not 
observed in the small tumour stratum is interesti
ng. 
The reasons for this are not clear, but it could
 be 
postulated that the clearance time of DDC is faster
 in 
small tumours, as the poorly developed tum
our 
vascula ture, which could 'trap' DDC in larger tumo
urs, 
probably does not yet exist in smaller tumours. 
It is also possible that the chance of penetrating
 a 
major draining blood vessel when administering the D
DC, 
and thus 'losing' the entire dose is greater in sma
ller 
tumours. In either of these events, there would 
be 
little opportunity for DDC to have any effect either a
s a 
radiosensitizer or as a radioprotector. 
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It is also possible that the hypoxic fraction of the 
tumour increases with increasing tumour size due to 
poorly developed tumour vasculature (Stanley et al., 
1979). If this is so, then the work of Evans (1985) is 
very relevant. He showed, using an excision assay that, 
in mice breathing 5 . 5 % 0 2 in nitrogen, there was a ten 
fold difference in survival of cells after radiation 
between DOC treated and untreated mice. This could be 
contrasted with a two fold difference in survival when 
air-breathing mice were used. The inference here was 
that DOC was more effective as a sensitizer under hypoxic 
conditions. 
There is also extensive evidence that radioprotection by 
thiols is related to the level of oxygenation at the time 
of irradiation (Denekamp et al., 1981a ; Lunec, 1981 
Parkins et al., 1983). Indeed, Durand (1983) and Durand 
& Olive (1989) have argued that thiols deplete the cell 
of oxygen, and that this is the mechanism of 
radioprotection by thiol compounds. 
If the larger tumours did indeed have a greater 
proportion of hypoxic cells, then a DOC pretreatment may 
have contributed to further hypoxia and therefore 
radioresistance in those tumours. 
rt has been shown that the duration of action of DDC did 
not exceed 3 hours, and that following oral 
administration, 60% of the dose was cleared in 3 hours 
148 
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and was excreted via the lungs and urine (Craven et al., 
1976). 
It is possible therefore that if the time between DDC 
administration and irradiation is 4 hours, the effect of 
DOC on oxygen status in the tumour would have normalised, 
allowing SOD inhibition to take the dominant place in 
determining the final response to the radiation. 
Conclusions 
A statistically significant time modulation effect of DOC 
has been demonstrated where DDC was protective if 
administered 1 hour prior to irradiation, and sensitized 
when administered 4 hours prior to irradiation. 
This effect was dependent on 
This could be a reflection 
oxygenation of larger tumours. 
the size of the tumour. 
of the lower level of 
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The effect of DDC pretreatment on the 
tumour bed effect 
In Chapter 8 the effect of the tumour bed effect (TEE) on 
the growth delay assay was discussed. It is known that 
the tumour response to modifying agents (sensitizers, 
protectors, hyperthermia, induced hypoxia etc) may modify 
stromal damage to a different degree compared with damage 
to tumour cells. 
& Terry, 1983 
This has been shown for WR 2721 (Begg 
Williams et al., 1984) . For this 
reason, it was decided to examine tumour growth delay 
following DDC pretreatment and radiation in a situation 
where either the tumour bed effect was absent, or where 
only the tumour bed effect was present - i.e. where the 
tumour cells were not exposed to radiation or DOC. 
These studies are discussed in this chapter. 
Methods 
BALB/c mice bearing the 3-methylcholanthrene induced 
rhabdomyosarcoma on the right hind leg were used in all 
experiments. Procedures concerning the maintenance of 
animals and tumours as well as the irradiation of mice 
and preparation of DDC for intratumoural administration 
have been described in Appendix 2. 
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In vivo excision assay 
The aim of this experiment was to examine tumour growth 
delay following treatment where the tumour bed effect was 
absent. 
Tumour-bearing mice were treated with DOC and 
irradiation, following which the mice were sacrificed and 
the tumours excised and cell suspensions prepared. 
These cell suspensions were then inoculated into the legs 
of untreated recipient mice. Tumour growth was then 
recorded as described previously. 
Assay procedure 
The tumour bearing mice were divided into treatment 
groups as follows : 
* No treatment. 
* 20 µl saline injected intratumourally prior to 15, 
25 or 35 Gy total body irradiation. 
* 100 mg/kg DOC injected intratumourally hour 
prior to 15, 25 or 35 Gy total body irradiation. 
* 100 mg/kg DOC injected intratumourally 4 hours 
prior to 15, 25 or 35 Gy total body irradiation. 
Six mice were used for each radiation dose in each 
treatment group. For the irradiations, mice were placed 
in an acrylic plastic box with dimensions 15 X 15 X 2.5 
cm. The box was closed with a 0.5 cm thick acrylic lid 
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which served as build up. Many small holes were drilled 
into the box to provide ventilation during irradiation. 
An air pump was also used to blow air into the box during 
irradiation. Total body irradiation (TEI) was performed 
with an Eldorado 6 60co source at an SSD of 80 cm. 
Mice were sacrificed by cervical dislocation and the 
tumours excised within 30 minutes of radiation. A 
tumour cell inoculum containing approximately 1. 6 X 10 6 
cells (Appendix 2) was injected into the right hind 
gastrocnemius muscle of 6 untreated recipient mice per 
treatment group. Tumour volume was measured three times 
per week until a volume of 0.6 cm3 was reached. 
Results 
The mean growth times following DDC and radiation 
treatment to the tumour prior to excision and 
re-inoculation into an untreated mouse are given in Table 
1 0. 1 . 
7 52 Chapter 7 0 
Table 10. 1. The mean growth times following treatment to the tumour prior to 
excision and re-inoculation into an untreated mouse. t-values are given where 
a significant difference between the DDC treated tumours and saline treated 
controls exits. 
Treatment prior to 
inoculation 
Control : no treatment 
20 .,..4) saline before 15 Gy 
100 mg/kg DDC 1 hr before 15 Gy 
100 mg/kg DDC 4 hr before 15 Gy 
20 p] saline before 25 Gy 
100 mg/kg DDC 1 hr before 25 Gy 
100 mg/kg DDC 4 hr before 25 Gy 
20 p!J saline before 35 Gy 
100 mg/kg DDC 1 hr before 35 Gy 
100 mg/kg DDC 4 hr before 35 Gy 
Mean growth time 
(days) 
10.5 '!. 0.6 
13.9!0.5 
15.6 1 0.5 
15.5 1 1.3 
17.9 t 0.8 
18.0 t 1.7 
17. 7 !: 0.8 
23.7 !. 2.7 
Significance 
t = 5.356 p<0.001 
t = 2.653 p<0.05 
N.S. 
N.S. 
3/6 tumours 'cured' 
4/6 tumours 'cured' 
A significant difference between growth times of DDC and 
saline treated mice was noted when the pre-inoculation 
radiation dose was 15 Gy. This difference was not seen 
when the pre-inoculation dose was 25 Gy. At even higher 
pre-inoculation doses, some tumours failed to grow within 
30 days. It was not possible to compare these groups 
with a Kaplan-Meier analysis as the censoring rate was 
above 30%. 
Fig. 10.1 and Fig 10.2 show the pattern of tumour growth 
following pre-inoculation treatment with DOC or saline 
and 15 or 25 Gy respectively. 
Tumour bed effect 153 
The difference between saline and DDC pre-treatment prior 
to 15 Gy is illustrated in both Figure 10.1 and Figure 
10.2. It is important to note that the slopes of the 
curves of all of the treated groups are the same as the 
untreated controls. This indicated that the tumour cells 
were proliferating at the same rate as the untreated 
controls, a characteristic of the absence of a tumour bed 
effect. 
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Figure 10. 1. The pattern of tumour growth following DDC or saline 
administration prior to 15 Gy gamma irradiation. The tumour was excised and 
re-inoculated into an untreated mouse prior to estimation of growth time. 
Each pcint is the mean of six determinations. Uncertainty bars have been 
omitted to preserve clarity. 
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Figure 10.2. The pattern of tumour growth following ODC or saline 
administration prior to 25 Gy gamma irradiation. The tumour was excised and 
re-inoculated into an untreated mouse prior to estimation of growth time. 
Each point is the mean of six determinations. Uncertainty bars have been 
omitted to preserve clarity. 
Methods 
The tumour bed effect assay 
The principles of the tumour bed effect have been 
described in chapter 8. In order to examine tumour 
growth delay after DDC pretreatment and irradiation to 
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the tumour bed only, the following treatment protocol was 
applied. 
A dose of 25 Gy was chosen as it was felt that this would 
definitely result in a visible TEE. The aim of this 
experiment was to examine whether DDC affected the TEE, 
and for this reason it was important that a clear TEE be 
demonstrated. Milas et al. ( 1986), using an MCA-4 
tumour which exhibits a strong TEE, showed that the TEE 
started to appear at 5 Gy, increased sharply with 
increasing radiation dose and approached a plateau at 
approximately 15 - 20 Gy. For this reason a dose of 25 
Gy was chosen. 
A dose of 100 mg/kg or 20 µl O. 9% saline was injected 
directly into the right hind gastrocnemius muscle either 
1 or 4 hours prior to irradiation of the leg with 25 Gy 
gamma rays. 
The mice were restrained in an acrylic plastic jig for 
leg irradiations in the same way as for leg tumour 
irradiations as described in Chapter 9. 
Twenty-four hours after irradiation, a tumour cell 
suspension containing approximately 1 .6 X 10 6 cells 
(Appendix 2) was injected into the gastrocnemius muscle 
of the irradiated leg. 
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Tumour volume was then measured three times per week as 
described in Chapter 8, until a volume of O. 6 cm
3 was 
reached. 
Four groups of 10 mice each were used in this experiment, 
and were placed into the following treatment groups : 
* No treatment. 
* 20 µl saline injected prior to 25 Gy irradiation 
to the right hind leg. 
* 100 mg/kg DDC injected hour prior
 25 Gy 
irradiation to the right hind leg. 
* 100 mg/kg DDC injected 4 hours prior to 25 Gy 
irradiation to the right hind leg. 
Results 
Table 10.2 shows the mean growth times of tumours 
following DDC or saline and 25 Gy irradiation of the 
tumour bed prior to tumour cell inoculation. No 
difference was detectable between DDC pretreatment or 4 
hours prior to irradiation, or between these treatments 
and the saline controls. 
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Table 10.2. The mean growth times of tumours following treatment to the 
tumour bed or stroma prior to tumour inoculation. 
Treatment prior to 
inoculation 
Control : no treatment 
20 µl saline before 25 Gy 
100 mg/kg DDC hr before 25 Gy 
100 mg/kg DDC 4 hr before 25 Gy 
Mean growth time 
(days) 
19.2 ± 0.6 
22.3 ± 2.8 
21.6 ± 1.6 
22.5 ± 2.2 
Figure 10.3 shows the pattern of tumour growth following 
inoculation. It can be seen that tumour cells 
inoculated into a pre-irradiated leg took longer to 
establish tumours than the controls, and further that 
their growth rate was reduced. 
evident when the tumours grew larger. 
This was especially 
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Figure 10.3 The pattern of tumour growth following DOC or saline 
administration prior to 15 Gy garrrna irradiation to the stroma or tumour bed. 
Each point is the mean of ten determinations. Uncertainty bars have been 
omitted to preserve clarity. 
Discussion 
The experiments in this chapter illustrate a more 
detailed analysis of tumour growth delay which enables 
the separate analyses of actual growth delay representing 
tumour cell kill and changes in growth rate representing 
stromal injury. For any clinical application of 
modifiers of the effects of radiation, it may be 
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important to distinguish between these two modes of 
action (Williams et al., 1984). 
A comparison of the growth curves from the excision 
assay, where TEE is absent and the TEE curve, where there 
is no direct injury to the tumour cells clearly shows 
these two modes of action. Figs. 1 0. 1 and 1 0. 2 show 
growth curves with similar slopes and no change of growth 
rate, whereas Fig. 10. 3 shows a reduced slope following 
irradiation of the tumour bed. Clearly, the results 
presented in the previous chapter represent a combination 
of these effects (see Fig 9.1). 
It was not possible to show that DDC made tumour cells 
sensitive to radiation in all repetitions of the excision 
assay (Table 10.1), nor were any significant differences 
between the two DDC pretreatment groups (DDC 
administration or 4 hours prior to radiation) detected. 
Fig 10.1 shows that DDC sensitized the tumour cells to 15 
Gy irradiation, tumours taking significantly longer to 
reach an endpoint volume 
pretreatment. 
of 0.6 after DDC 
An important feature of the excision assay described here 
is that the tumours were all greater than 0.3 cm3 at the 
time of irradiation and probably had a fair proportion of 
hypoxic cells. In chapter 9, tumour sensitization was 
only noted in the 'larger' tumour stratum (volume= 0.230 
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3 - 0. 300 cm ) , and it was argued that DOC may be more 
effective as a sensitizer under hypoxic conditions. 
The fact that no effect of DOC on the stroma could be 
demonstrated could also be a reflection that the response 
of cells to DOC and radiation is dependent on the level 
of oxygenation of the tissue, as it is most likely that 
the irradiated muscle in this experiment was well 
oxygenated. 
Conclusion 
The action of DOC in modifying the radiation response of 
tumours is due to a change in sensitivity of the tumour 
cells rather than the tumour bed or stroma. 
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Survival after DDC administration 
The protective effect of DOC against total body 
irradiation (TEI) has been recognised for almost 35 
years. One of the earliest reports is that of Van 
Bekkum (1956), who showed that DOC protected mice 
significantly against the lethal effects of total body 
irradiation. Recent reports corroborate this finding, 
for example Evans et al. ( 1983a) showed that 100 mg/kg 
DOC injected 30 minutes before TEI increased the Lo50130 
from 7. 8 Gy to 14. 9 Gy. The Lo50130 is the dose of 
radiation required to kill 50% of the mice within 30 
days. 
In view of the results of the previous chapters, showing 
a time-modulation effect of DDC, it was decided to 
investigate whether a time delay of 4 hours prior to 
irradiation would reverse this protective effect. 
Objectives 
* To examine the effect on mouse survival of DOC 
administered or 4 hours prior to total body 
irradiation as measured by the LD 50130 assay. 
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Methods 
Experimental animals and DDC pretreatment 
CS7/Bl mice, bred and maintained as described in Appendix 
2 were used in the survival experiments. 
DDC solutions for intraperitoneal administration were 
prepared as described in Appendix 2. The DDC was 
administered intraperi toneally in a total volume of 100 
µl. 
Total body irradiation 
Seven to eight mice were placed in an acrylic plastic jig 
at a time for total body irradiation as described in 
Chapter 10. Fifteen mice were used for each dose 
point. Mouse mortality was checked daily for 30 days. 
Radiation dose response curves for lethality were 
constructed and fitted by probit analysis as described by 
Finney ( 1971) These were used to calculate the values 
of LD 50 ; 30 . Linear
 regression analysis was performed on 
the probi ts of response versus the natural logarithm of 
the dose, and the correlation coefficient calculated 
( Finney , 1 9 71 ) . 
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Results and Discussion 
Table 11 .1 shows the results of an experiment where 
various doses of DDC were injected i.p. into mice 4 hours 
prior to 7.5 Gy gamma irradiation. 
Table 11. l. Survival after treatment with various doses of DOC, followed by 
7.5 Gy total body irradiation 4 hours later. 









In most cases DDC offered some protection against the 
effects of total body irradiation, however this 
protection was minimal at a dose of 500 mg/kg where 1 O 
out of 15 mice succumbed to the treatment. When the 
dose was increased to 1000 mg/kg, DDC again strongly 
protected the mice. For this reason, 500 mg/kg was the 
dose of DDC chosen for the Lo50130 determinations. 
The results of probit analysis for determination of the 
LD 50 ; 30 are given in Table 11 .2 and Fig. 11 .1. 
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Table 11.2. LD50130 values for C57/Bl mice exposed to total body irradiation 
with and without prior treatment with DOC. 
Treatment 
Radiation (RT) only 
500 mg/kg DOC 1 hr before RT 
500 mg/kg DDC 4 hr before RT 
500 mg/kg DOC immediately after RT 
When DOC was administered 
LD50130 i SD 
7. 50 ! 0. 08 Gy 
8.96 ! 0.20 Gy 
7. 93 :!: 0. 19 Gy 
7. 80 i. 0. 21 Gy 
correlation coefficient 





hour prior to total body 
irradiation, a moderate degree of protection was obtained 
(DMF = 1 .2 at LDso>· 
No significant differences between the Lo50130 values 
were detected between mice treated with DOC 4 hours prior 
to irradiation and mice treated with radiation only. 
DOC given immediately after irradiation was not found to 
effect the Lo50130 value significantly. 
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Figure 11. 1 Isoeffect curves for lethality in C57/B1 mice after 500 mg/kg DDC 
administered 1 or 4 hours prior to radiation or radiation only. Bars 
represent LD50130 t S. D. 
These results are in agreement with those of Evans et al. 
(1983a) who were unable to show any significant 
radioprotection at a dose of 500 mg/kg DDC 30 minutes 
before TEI, but maximum protection at a dose of 1000 
mg/kg DDC. 
The data did not show any sensitization to the effects of 
TEI by DDC, and in all cases DDC pretreatment resulted in 
some degree of protection. 
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The lower Lo50130 for DOC pretreatment 4 hours prior to 
irradiation compared to DOC pretreatment 1 hour prior to 
irradiation is probably an indication that most of the 
DOC was metabolised by the time of irradiation. No time 
modulation effect of DOC is suggested by these results. 
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Chapter 12 
In vitro responses to DDC and irradiation 
In Chapter 6 it was hypothesised that radiosensitization 
could occur as a result of SOD inhibition by DDC, but 
could be masked by a radioprotective effect if the tissue 
levels of DOC were too high at the time of irradiation. 
This section sets out to examine whether cells in culture 
can be sensitized to radiation by DOC pretreatment if DOC 
is removed prior to irradiation. 
Objectives 
* To determine the survival of B16 mouse melanoma 
cells after irradiation when the cells have been 
pretreated with DOC and the DOC washed out of the 
medium prior to irradiation. 
* To examine the effect of a time interval of either 
one or four hours between DOC administration and 
irradiation. 
Methods 
Procedures used for the routine maintenance and treatment 
of cells are described in Appendix 3. 
Briefly, these investigations concerned the response of 
B16 mouse melanoma cells after having been exposed to 
various concentrations of DOC in serum-free McCoys SA 
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medium for 45 minutes at 37°C. The response of the 
cells to radiation was assessed after DOC was removed by 
3 successive washings in Hanks Balanced Salt Solution 
(HESS) and the cells re-incubated in DOC-free, serum 
containing medium for either 1 or 4 hours. 
Results and Discussion 
Figure 12. 1 shows the survival of B 16 mouse melanoma 
cells following exposure to concentrations of DOC ranging 
from 10-9M to 1 o- 3M for 45 minutes at 37°C. It was 
noted that low concentrations of DOC (10- 9M 10-8M) 
actually enhanced the survival of cells to above that of 
control levels. 
increased. 
At higher concentrations, DOC toxicity 
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Figure 12. 1 Survival of B16 cells after incubation with various 




Figure 12.2 shows the response of B16 cells to 10-
6M DOC 
pretreatment for 45 minutes prior to gamma irradiation. 
In the case of the DOC pre-treated cells, the survival 
fractions were calculated as ratios of survival after DOC 
plus radiation to survival after DOC only. This 
normalisation of the DOC pre-treatment curve was done to 
allow assessment of the radiation effect once the effects 
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Figure 12.2 Survival curves of B16 cells after pretreatment with l0-6M DDC 
for 45 minutes followed by a 1 hour (solid line) or 4 hour (dotted line) delay 
before irradiation (RT) (dashed line) Points represent the mean of 3 
replicates. 
Stone et al. (1978) asserted that a large concentration 
of DDC must be present at all times to maintain the 
inhibitory effects of SOD in order to cause 
radiosensitization. These investigators were unable to 
show sensitization of erythrocytes to radiation 
haemolysis when DDC was washed off the erythrocytes prior 
to radiation, whereas a substantial haemolysis was noted 
when DDC was present during irradiation. 
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The results observed in erythrocytes may not be 
applicable to other cell types, as was found in the work 
described here. Fig. 12.2 shows that even when DDC was 
washed off the cells by 3 successive washes in HESS, a 
substantial enhancement of radiation induced lethality 
was noted. The DOC pretreatment sensitized the cells 
with a DMF (dose modifying factor) of 1.4 when the time 
between DDC exposure and radiation was 
Appendix 3 for the calculation of DMF). 
hour (see 
When the cells 
are incubated in DOC-free medium for four hours prior to 
irradiation, this sensitization was even greater (DMF = 
2 .5). 
Analysis of the curves in Fig 12.2 show that DOC modified 
both the slope and shoulder of the curve. This result 
is consistent with that of Lin et al. (1979b) who studied 
cells that were irradiated in the presence of DOC. Lin 
et al. (1979b) argued that the ultrastructural changes in 
the mitochondria induced by DDC ( see Chapter 4) were 
similar to those of cells following exposure to 
hyperbaric oxygen. Westman & Marklund (1983) found 
that by exposing erythrocytes to 3 X ·1 a- 3M DDC for 90 
minutes produced a 98% inhibition of SOD, and SOD 
activity was only 10% of control activity 24 hours later. 
This suggests that the increased sensitivity to 
irradiation, even 4 hours after DOC pretreatment, must be 



















The observation that low concentrations of DDC appear to 
increase cell survival (Fig. 12.1) is consistent with the 
work of Rigas et al. (1979) and Allalunis-Turner & 









0 RT only 
X DOC + 1 hour + RT 
0 DOC + 4 hours + RT 
0.01 
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-7 Figure 12.3 Surviv~l curves of 816 cells after pretreatment with 10 M DDC 
for 45 minutes followed by a 1 hour (solid line) or 4 hour (dotted line) delay 
before irradiation (RT) (dashed line) Points represent the mean of 3 
replicates. 
When a lower concentration (10- 7M) was used for DDC 
pre-treatment, (Fig. 12.3) the effect was much the same, 
except that the addition of a 4 hour gap between DDC and 
radiation did not result in as great a sensitization as 
that seen after 1 o-6M DDC. The slope of the curve was 
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also not as greatly 
concentration of DDC, 
was still evident. 
Conclusion 
reduced as with the higher 
yet the decrease in the shoulder 
It appears therefore, that DDC pretreatment can sensitize 
cells to radiation even when DDC has been washed away, 
and that this sensitization is still seen when a time 
interval is allowed between DDC pretreatment and 
irradiation. It is suggested that this is probably due 
to a lowered SOD activity. 
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Chapter 13 
DDC and Hyperthermia 
There is currently great interest in hyperthermia as a 
treatment modality in cancer. It is clear that the mode 
of action or the 'hyperthermia target' resulting in cell 
death may be different to that for ionizing radiation. 
However there are some indications that heat damage may 
be modulated or influenced by superoxide (references 
below). In view of the effect of DDC on SOD, it was 
considered of great interest to further investigate the 
effect of DDC on the heat response of cells in culture. 
In this chapter, these studies are detailed. 
Rationale for DDC as a heat sensitizer 
McCord et al. ( 1973) showed that cells with lowered SOD 
activity may be more susceptible to thermal damage than 
other cells, and postulated that inhibition of SOD by DDC 
might act as a heat sensitizer. 
investigators have examined this. 
A number of 
Hahn et al. ( 1975) showed that hyperthermia altered the 
penetration of bleomycin and adriamycin into mammalian 
cells. Lin (1979a) extended this reasoning and 
postulated that if more DDC enters the cell as a 
consequence of heat treatment, more SOD would be 
inactivated. This seemed to be consistent with the 
results of (Ciborowski et al., 1978) which showed a 
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greater inhibitory effect on SOD activity in cells 
exposed to increased temperatures. 
Evans et al. ( 1983b) showed that if DDC was present in 
the medium for 1 hour before, but removed prior to heat 
treatment, the same survival curve as after treatment 
with heat alone was obtained, indicating that DDC had to 
be present on the cells during heat exposure to be of any 
effect. They argued that this rendered a mechanism 
involving lowered levels of SOD to explain heat 
sensitization by DDC very unlikely. Instead, they 
argued for a mechanism where DDC had the ability to 
affect the repair of potentially lethal damage in cells 
following heat exposure. 
Kapp & Hahn ( 1979) showed that various thiol compounds 
including cysteamine, 2-aminoethylisothiourium bromide 
and cysteine could enhance hyperthermia-induced cell 
killing. They showed that the drugs alone were not 
toxic at 37°C, however a marked potentiation of heat 
killing by these compounds was seen at temperatures above 
42°c. 
Mitchell & Russo ( 1983) asserted that exogenous thiols 
potentiate thermal killing via a peroxide producing 
reaction involving the formation of a thiol-Cu complex. 
Issels et al. (1984) suggested that superoxide and 
hydrogen peroxide, generated by the autooxidation of 
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thiols in the presence of oxygen are involved in the 
potentiation of heat killing. 
As far as DOC itself is concerned, Lin et al. (1979a) 
showed that when DON cells were exposed to 43°C in the 
presence of DOC, a marked increase in cell killing was 
noted when compared with either exposure to DOC or 4 3 ° C 
alone. 
Lin et al. (1985) showed a biphasic toxicity of DOC (see 
chapter 4), where DOC was toxic at concentrations of 1 X 
1 o- 5M and greater than 1 X 1 o- 3M, but not at 
concentrations of X 10- 6M and X 10- 4M. The 
combination of DOC and other cytotoxic agents such as 
radiation, adriamycin, bleomycin, as well as hyperthermia 
enhanced cell kill in 
concentrations (1 X 10-5M 
the 
; > 
two cytotoxic ranges of 
1 X 10- 3M). It was argued 
that this may represent an important mechanism of DOC 
toxicity that is independent of the toxic effects caused 
by DOC-induced SOD inhibition or the action of DOC as a 
thiol compound. 
Objectives 
* To examine the effect of DOC on cells following 
exposure to heat, where DOC was washed off the 
cells prior to heat exposure. 
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Methods 
Procedures used for the routine maintenance and treatment 
of cells are described in Appendix 3. 
Briefly, these investigations concerned the response of 
B16 mouse melanoma cells after DOC and heat treatment. 
The cells were exposed to various concentrations of DOC 
in serum-free McCoys SA medium for 45 minutes at 37°C. 
The response of the cells to immersion in a water bath at 
43°C for O - 60 minutes was assessed after DOC had been 
washed off and the cells reincubated in DOC-free, serum 
containing medium for either 1 or 4 hours. 
Results and Discussion 
Fig 13.1 shows the response of cells to either 43°C alone 
or pretreatment with 1 o- 4M DDC for 45 minutes or 4 
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Figure 13. 1 Survival of 816 cells after pretreatment with 10-4M DDC for 45 
minutes at 37°C followed by a 1 or 4 hour delay before hyperthermia (43°C). 
Bars represent the meant S.D. of 3 replicates. 
Survival fractions of the 'heat only' curve were 
calculated after 'sham-DDC pretreatment' (i.e. cells were 
exposed to serum-free medium for 45 minutes, followed by 
3 successive washings in HESS) . When a time delay of 
only hour was allowed between DDC incubation and 
hyperthermia, an enhanced cell kill was seen at heat 
exposures for 45 or 60 minutes. However when the time 
between DDC incubation and hyperthermia was 4 hours, this 
enhancement of cell kill was not seen. 

















Fig. 13. 2 shows the survival of cells after incubation 
with 1 o-6M to 1 o- 3M DDC for 45 minutes followed by a 1 
hour delay in DOC-free medium at 37°C before exposure to 
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Figure 13.2 Survival of 616 cells after pretreatment with various 
concentrations of DDC for 45 minutes at 37°C followed by a 1 hour delay before 
hyperthennia (43°C) of varying durations. Points represent the mean of 3 
replicates. 
Low concentrations of DDC ( 1 X 1 o-6M and 
enhanced the survival of heat treated cells. This has 
been demonstrated before, where DDC was shown to 
stimulate cell growth, possibly due to an ability to 



















1984). It is probably not an expression of 
thermoprotection. Incubation with higher concentrations 
of DDC ( 1 X 1 o- 4M and x 1 a-3M) on the other hand 






15 minutes D 
0.01 30 minutes 
45 minutes 




0 10-6 10 -5 10-4 10-3
 
DOC CONCENTRATION 
Figure 13.3 Survival of B16 cells after pretreatment with various 
concentrations of DDC for 45 minutes at 37°C followed by a 4 hour delay before 
hyperthermia (43°C) of varying durations. Points represent the mean of 3 
replicates. 
When a 4 hour delay was allowed between DDC pretreatment 
and hyperthermia, the enhanced survival seen at low 
concentrations of DDC was not as great as when the delay 
was 1 hour. Incubation with 1 X 10-
4M DDC 4 hours prior 
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to hyperthermia no longer enhanced the heat toxicity, 
however at higher concentrations ( 1 X 1 a- 3M), DDC again 
enhanced the toxic effects of hyperthermia. 
These results show that DOC can sensitize cells to 
hyperthermia treatment, and this is evident even when DOC 
is washed off the cells prior to hyperthermia. This is 
in contrast to the work of Evans et al. ( 1983b) who 
exposed Chinese hamster cells in Eagle's MEM (minimum 
essential medium) or HESS to DOC and temperatures of 
43°c. They showed that DDC had to be present during 
heat exposure in order for it to have any effect. 
It could be argued however that a thiol-Cu complex of the 
type suggested by Mitchell & Russo ( 1983) involving DDC 
might have formed during exposure to DDC. Indeed, 
McCoys SA medium, used in this work, contains more copper 
than HESS or MEM (Eiaglow et al., 1984), the medium used 
by Evans et al. ( 1983) . This DOC-copper complex could 
have become protein-bound, 
washing. 
and thus remained after 
Activated oxygen species such as superoxide and hydrogen 
peroxide are also produced during the autooxidation of 
thiols in the presence of oxygen ( Issels et al., 1984 ; 
Eiaglow et al. , 1984) . This is relevant as a situation 
may arise where a DDC-Cu complex is involved in producing 
reactive oxygen species, whose toxicity may be 
exacerbated by the fact that SOD is inhibited. 
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It has been shown that hyperthermia treatment can cause 
the production of superoxide in CHO cells treated with 
45°C for 15 minutes (Loven et al., 1988). The addition 
of exogenous SOD was found to increase survival 
approximately 2 fold following heat exposure ( Downes & 
Loven, 1988). 
Conclusion 
DOC is a potential heat sensitizer. It is not clear at 
this stage whether this is due to an inhibition of SOD, 
or due to potentiation of heat killing by thiol oxidation 
or both. Further studies in this direction are 
warranted. 
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Overview and implications of this work 
This study has concerned itself primarily with the 
inhibition of superoxide dismutase by 
diethyldi thiocarbamate in order to sensitize tumours to 
ionizing radiation. 
The use of DDC as an inhibitor of SOD has however meant 
that any sensitization resulting from SOD inhibition 
could be masked by a radioprotective effect by DDC. 
This contradiction has been the cause of a debate over 
the last few years on the potential use of DOC as a 
radiosensitizer or as a radioprotector in the clinic. 
The inhibition of SOD by DOC was confirmed in a murine 
tumour, and it was shown that this inhibition can be 
maintained for up to twenty-four hours after DOC 
administration. This indicated that there was a 
potential for the radioprotective effect of DOC to be 
overcome, if the levels of DDC were low enough at the 
time of irradiation. 
Indeed, if DOC was removed from the growth medium of 
cells in culture prior to irradiation, a significant 
sensitization was demonstrated. 
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Perhaps the most important contribution of this thesis to 
the debate on the role of DOC is that it was shown that 
DOC could act as both a radiosensitizer and as a 
radioprotector in the same experiment. 
action of DOC was found to be dependent 
The dominant 
on the time 
allowed between DOC administration and irradiation. If 
this time was approximately 4 hours, 
show a radiosensitizing effect by 
growth delay assay. 
it was possible to 
means of a tumour 
In addition, DOC was found to modify the radiation 
response of tumour cells, rather than the stroma or 
tumour bed. The time modulation effect of DOC was shown 
in larger tumours, rather than smaller tumours, which 
could mean that tumour oxygenation is an important 
criterion in determining the response to radiation of DOC 
treated cells. 
This work suggests that some caution should be exercised 
when DOC is put forward as either a radiosensitizer or a 
radioprotector in the clinic. 
however, suggests that DOC 
The work on hyperthermia 
may have potential as a 
thermosensitizer, and further investigations in this 
regard are warranted. 
The work on tumour growth delay also demonstrated the 
inadequacy of the current methods of analysis of tumour 
growth delay data. It is hoped the use of the Kaplan-
Meier method to analyse tumour growth delay data will 
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become one of the standard methods of analysing growth 
delay assays with censored data. 





Homogenising buffer: 0.05 M K2HP04 / 1 X 10-
4 M EDTA: 
8.709 g K2HP0 4 , 0.0372 g EDTA w
ere dissolved in water and 
made up to 1 litre. pH was adjusted to 7.8 with KOH 
0.5 M Na2co3 / 1 X 10-
5 M EDTA buffer : 
4.2 g Na2co3 , 0.00372 g EDTA were dissolved in water and 
made up to 1 litre. pH was adjusted to 10.2 with NaOH 
0.55% (w/v or 3 X 10- 4 M) adrenalin solution : 
5.5 mg adrenalin (Sigma, St.Louis, Mo.) was added to a 
solution of water acidified to pH 2. 0 with perchloric 
acid ( 41 µl perchloric acid + 5 ml water) to prevent 
autooxidation. 
assay. 
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1.36 g KH2Po4 , 2.25 g KCl were dissolved in water and 
made up to 1 litre. 
concentrated KOH 
pH was adjusted to 8.0 with 
50 mM potassium phosphate buffer : 
27.21 g KH2Po4 was dissolved in water and made up to 1 
litre. pH was adjusted to pH 7.0 with concentrated KOH. 
This resulted in a 0.2 M stock solution, but was used as 
0.5 ml/2 ml. 
1 mM EDTA: 
37.2 mg EDTA dissolved in 10 ml water. 
1 mM NaN3 : 
6.5 mg NaN3 dissolved in 10 ml water. 
0.2 mM NADPH : 
16.7 mg NADPH dissolved in 10 ml water. 
1 mM glutathione 
30.7 mg GSH dissolved in 10 ml water. 
unit/ml Glutathione reductase : 
µl of a GSSG-r solution with an activity of 2000 
units/ml added to a 2 ml sample gave this concentration. 
0.25 mM H2o2 : 
0.267 ml (30% w/v) H2o2 was made up to 
water. 
litre with 
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Catalase 
Reagents 
Homogenising buffer : 10 mM KH 2Po4 / 30 mM KCl : 
1.36 g KH 2Po4 , 2.25 g KCl were dissolved in water and 
made up to 1 litre. pH was adjusted to 8. 0 with 
concentrated KOH 
50 mM tris hydroxymethyl methylamine 
0. 606 g Tris was dissolved in 100 ml water and the pH 
adjusted to 7.4 with concentrated HCl. 
10 mM H2o2 : 
1 .05 ml (30% w/v) H2o2 was made up to 1 litre with water. 
Fluorometric protein assay 
The basis of this assay is the reaction of fluorescamine 
(4-phenylspiro[furan-2(3H),1 '-phthalan)-3,3'-dione) with 
substances containing primary amino groups to yield 
highly fluorescent products as described by Bohlen 
(1973). The relative fluorescence during this reaction 
is highest at pH 8. 
Reagents 
Standard protein solution 
1 mg bovine serum albumin dissolved in 1 ml water. 
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0.05 M sodium phosphate buffer 
7. 8 g NaH2PO 4 • 1 OH20 ( or 5. 99 g anhydrous NaH2PO 4 ) was 
dissolved in water and made up to 1 litre. pH was 
adjusted to 8.0 with concentrated NaOH. 
Fluorescamine 
Fluorescamine, being insoluble in water was dissolved in 
dioxane, a water-miscible organic solvent. 
30 mg fluorescamine was dissolved in 100 ml dioxane, 
whereafter it was stored in a glass beaker blacked out 
with aluminium foil as the solution is light sensitive. 
Assay Procedure 
10-250 µl aliquots of the sample or a standard protein 
solution were transferred to glass test-tubes and the 
volume adjusted to 3 ml with NaH2Po4 buffer. ml 
fluorescamine was added to the buffered protein solution 
while being stirred with a vortex mixer to ensure rapid 
mixing. 
Perkin-Elmer 
The fluorescence was measured using a 
Fluorescence Spectrophotometer at an 
excitation wavelength of 
wavelength of 475 nm. 
390 nm and an emission 
Sample protein concentrations 
were estimated by comparison to the standard curve. 
Spectrophotometric protein assay 
The basis of this assay is the reduction of Falin phenol 
reagent by copper-protein complexes at pH 10. 
causes a colour reaction which can be 
This 
measured 
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spectrophotometrically as described by Lowry et al. 
(1951). As the reduction of Folin reagent liberates 
acid, the solution must be well buffered to maintain 
colour changes. 
Reagents 
Standard protein solution 
1 mg bovine serum albumin dissolved in 1 ml water. 
Solution A : 2% Na2C03 in 0.1 M NaOH. 
4 g Na2co3 , 0.8 g NaOH 
were dissolved in water and made 
up to 200 ml. To this was added 2 ml 1% Cuso4 and 2 ml 
2% NaK tartrate. 
Solution B : 1 :1 Folin reagent. 
10 ml Folin reagent was added to 10 ml water and vortex 
mixed. 
Assay procedure 
Protein samples are added to 5 ml of solution A, and the 
volume adjusted to 6 ml with water in glass test tubes. 
This was allowed to stand at room temperature to allow 
the 
protein+ copper <~~~> protein-copper 
reaction to occur. After 12 minutes 0.5 ml of solution 
B is added and vigorously agitated. After 45 minutes 
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the absorbance was measured spectrophotometrically at 750 
nm. All protein determinations were made so that the 
amounts ranged from O. 05 mg to O. 25 mg, thus falling 




Experimental animals and tumours 
All procedures on animals described in this thesis 
were 




BALB/c mice were used in all tumour growth d
elay 
All mice were bred in a specified experiments. 
pathogen-free mouse unit and maintained in th
e 
Radiobiology Laboratories of the University of Cape 
Town 
Radiotherapy Department. Mice were fed with Epol M
ouse 
cubes and water was allowed ad libitum. The temperatu
re 
in the mouse unit was maintained at 22°C. Mice used
 in 
these studies were 6 weeks old with a weight range
 of 
18-22 g before any procedure took place. 
3 methylcholanthrene induced rhabdomyosarcoma 
A transplantable 
injecting 0. 1 ml 
rhabdomyosarcoma was 





3-methylcholanthrene in arachis oil into the flanks
 of 
male BALB/c mice. It was found that a rhabdomyosarc
oma 
developed in all mice in approximately 3-4 months. 
The 
tumour was maintained by serial passage as descr
ibed 
below. 
Tumour bearing mice were sacrificed by prolonged expo
sure 
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to ether, after which tumours were removed by surgical 
excision. Any obviously necrotic tissue was discarded. 
Tumours from 3 animals were placed in petri dishes 
(Falcon Plastics) and finely chopped with crossed scalpel 
blades in approximately 5 ml of McCoys SA medium. (pH 7.2 
7. 4). After chopping, the total preparation was 
aspirated through a 1. 2 X 38 mm needle into a sterile 
syringe, and transferred to a sterile test tube where the 
aspirate was allowed to settle for a few minutes. 
25 µl of the upper layer of this aspirate ( 1 . 6 X 10 6 
cells) was inoculated into the right hind gastrocnemius 
muscle. 
inoculation. 
Tumours appeared 10 20 days after 
This site was convenient as it was very 
easy to measure the tumours and it was not necessary to 
anaesthetise the animal during treatment. 
appeared to cause little distress to the animal. 
It also 
Preparation of DOC solutions for intratumoural 
administration 
Solutions of DOC were made up at concentrations of 50, 
100 and 150 mg/ml in 0.9% saline. A 20 µl 
intratumoural injection resulted in a dose of 50, 100 and 
150 mg/kg respectively for a mouse weighing 20 g. 
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Cell Culture Techniques 
Cell line and tissue culture techniques 
The B16 mouse melanoma cell line is an established line 
and can be cultured in vitro using standard cell culture 
methods as outlined by Freshney (1987). 
The cells were maintained routinely in 50 ml plastic 
tissue culture flasks (Falcon) in McCoys SA medium 
(Gibco) with L-glutamine made up in 2.2 g/1 sodium 
bicarbonate buffer, supplemented with 20 ml/1 antibiotics 
( 100 U/1 penicillin, 100 µg/1 streptomycin and 100 µg/1 
neomycin) and 10% foetal calf serum (Gibco). The cells 
were incubated in a humidified atmosphere containing 95% 
air and 5% co2 at 37°C. 
Harvesting of Cell cultures 
Confluent stock cultures were detached from their flasks 
and harvested using the following procedure. Medium was 
poured off, and the cells rinsed twice with 2 ml 
trypsin/EDTA solution. 
for 5 minutes at 37°C. 
The cells were then incubated 
This resulted in the cells 
becoming detached from the bottom of the flasks. The 
cells were resuspended in 1 0 ml McCoys SA medium with 
antibiotics and 10% FCS. A sample of the cell 
suspension was taken and counted in a haemocytometer. 
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After appropriate dilutions were made, 5 ml aliquots of 
cell suspension in McCoys SA medium which contained 500 
cells were pipetted into 50 ml plastic tissue culture 
flasks. These flasks were incubated for 24 hours to 
allow cell plating to occur before any procedure was 
performed. 
Treatment 
Preparation of DDC Medium 
A 10- 2 M DOC solution was made up in distilled water and 
sterilised by ultrafiltration. This stock solution was 
further diluted with serum-free medium as required. 
DDC pretreatment 
After 24 hours the medium was poured off the flasks and 
replaced with either DOC medium in the case of 
experimental flasks, or serum-free medium alone in the 
case of controls. They were then incubated for 45 
minutes at 37°C in 95% air and 5% co2 whereafter the 
cells were rinsed three times in 2 ml Hanks balanced salt 
solution (HESS), before 5 ml fresh serum containing 
medium was added. 
Irradiation 
At one or four hours after DOC pretreatment, the flasks 
were irradiated with O - 8 Gy using a Siemmens Gammatron 
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Cabal t source with a dose rate of O. 4 Gy /min. The 
cells were then incubated for 12 days at 37°C in 95% air 
and 5% co2 before being stained and counted. 
After 7 days the medium was replaced with fresh medium. 
Hyperthermia 
A Labotec water bath with a temperature regulator (± 
0.1°C) was used for hyperthermia treatments. The screw 
tops of the culture flasks were tightly closed, and 
placed in the water bath so that the level of water was 
just above the level of the medium. 
this situation for 15 - 60 minutes. 
Staining and counting 
Flasks were kept in 
Medium was poured off and the cells rinsed with 3 ml 2% 
phosphate buffered saline before being fixed in methanol 
and acetic acid for 15 minutes. They were then stained 
with an amide black solution for 30 minutes, after which 
they were rinsed again in methanol and acetic acid. They 
were then allowed to dry, whereafter the number of 
colonies in the flask, representing the number of cells 
surviving in the plated suspension after treatment 
(Freshney, 1984), was counted. 
Plating efficiency was defined as 
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No. of colonies counted after no Rx 
No. of cells originally plated. 
The survival data was then fitted by non-linear least 
squares regression to the linear quadratic model of 
Chadwick and Leenhouts (1981) 
ln(SF) = -(aD+BD2 ) 
Dose response analysis 
The dose modifying factor (DMF) could be calculated at 
specified biological endpoints (i.e. survival levels) 
from the ratio of the doses following treatment with 
radiation only to the doses following pretreatment with 
DDC. In these investigations, for each pair of survival 
curves, the DMF was determined at 15 survival levels (0.9 
to 0.001), and the mean DMF then calculated. 
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Statistical considerations 
This appendix describes the rules followed when 
calculating any descriptive statistics in the discussion 
of data used in this thesis. 
Measures of central tendency 
In all discussion of central tendency, the mean, median 
and standard deviation was used. 
follows. 
Mean 
Mean: x = (r:x) /n 
These are defined as 
where xis each value, and n is the number of 
observations. 
Median 
The median is defined as the ( n / 2 + 0. 5) th
 observation 
when the observations are ordered from smallest to 
largest. When (n/ 2 + 0.5) i
s not equal to an integer, 
the mean of the values lying in positions (n/2 ) and (n/2 
+ 1) is used as the median value. 




where x, n and x are defined as the mean, total number of 
observations and each observation respectively. 
Statements of probability 
When the set of observations follow a normal 
distribution, certain multiples of the standard deviation 
(e.g. 1 .96 X SD= 95%) mark certain limits in the scatter 
of observations. 
When comparing an individual observation against a sample 
mean, the 95% confidence interval is used. 
defined as 
95% confidence= x ± (1 .96 SD) 
This is 
When comparing means of different sets of observations, 
the following parameters are used. 
Standard error of the mean SEM =SD/ ./n 
The 95% confidence limits of the mean when n>30, is 
95% confidence (mean) = x ± (1 .96 SEM) 
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When small sample sizes are used, the t distribution is 
· used to calculate the multiples of SEM needed for 95% 
confidence limits. 
Difference between means 
For large samples (n>60) 
In order to determine whether two sets of observations 
originate from different populations, the difference 
between the means is calculated 
and the standard error of the difference between the 
means. : 
+ 
where the SD 1 and SD2 are the
 standard deviations of the 
two samples, and n 1 and n 2 are the n
umber of observations 
in each sample. 
The number of multiples of the SEdiff this difference 
represents is calculated. If it is greater than 1 .96, it 
is said to be significant at the 5% level. 
0.01; 3.291 : p = 0.001) 
(2.576 : p = 
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For small samples (n<60) the t-test 
For smaller samples, where more chance variation must be 
allowed for, the multiples of standard deviation used 
before are not entirely accurate and the t-distribution 
is used when statements of probability are made. 
t = 
The table oft distributions is entered at (n 1-1J+(n2-1J 
degrees of freedom. 
The correlation coefficient 





with x representing the values of the independent 
variable, and y representing the values of the dependent 
variable. 




Kaplan Meier analysis of survival data 
In this discussion of the Kaplan-Meier method, for the 
sake of clarity, patient survival after a course of 
treatment is discussed, however 'patient survival' may be 
substituted for 'mouse not having attained a response 
(tumour size~ 0.6 cm
3 )' in the growth delay experiments. 
The method of Peto ( 1984) was used to calculate the 
Kaplan Meier survival curve. The method follows from 
the observation that in order to survive one year, a 
patient has to survive the first day, and the second and 
the third and so on to the 365th day. 
The separate probabilities of surviving each day are 
multiplied together giving: 
p(365) = e(1) X e(2) X e(3) X ....... X e(365) 
where p(365) is the probability of surviving for a full 
year, and e(n) is the estimated probability of surviving 
on day n. 
On day 1, we assume that all patients are alive at the 
start of treatment. 
surviving day 1 is : 
Therefore the probability of 
(no. of patients) - (no. of deaths on day 1) 
e ( 1) = 
(no. of patients) 
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On subsequent days, 
observation decreases. 
the number of patients under 
For example, on day n: 
* Some patients may have died on or before day n 
(responses). 
* Some patients may have started treatment less than 
n days ago (withdrawals). 
* Some patients may be lost to follow up, and the 
last information concerning their status was less 
than n days after treatment (withdrawal). 
For each day we calculate a probability of surviving, we 
therefore have to know how many patients are 'at risk'. 
The number of patients 'at risk' on day n is the number 
who were still alive and under observation at the 
beginning of the nth day. 
Patients who die or are withdrawn on the nth day are 
therefore at risk on day n, but not on day (n+1). 
i.e. Rn= R(n-1) - D(n-1) - W(n-1) 
where R = no. 'at risk' 
D = no. of deaths 
W = no. of withdrawals. 
The probability of surviving on day n is therefore 





If there are no deaths on day n, then e(n) = 1, and the 
value of p(n) remains unchanged as : 
p( n) = e( 1 ) X e( 2) X • • 
R(l) - D(l) 
or p(n) = ~--------- X 
R( 1) 
X e(n) 
R(2) - D(2) 
R(2) 
X ••• X 
R(n) - D(n) 
R(n) 
EQN. A 
It is therefore necessary to calculate the estimated 
probability of survival on day n only when D(n) > 0. 
An example using tumour growth delay data 
In this example, a response is defined as the attainment 
of a tumour volume of O. 600 cm
3 . In a group of 25 
tumour bearing mice, the first 3 mice to reach this 
volume do so 5, 
respectively. 
7 and 11 days after treatment 
In order to demonstrate how censored (tumour cure/ mouse 
escaped/ intercurrent death) data is dealt with, let us 
assume that one mouse escaped on day 9. 
The probability curve is calculated in the following way 
Time Equation A Probability Curve p(n) 
day 0 25/25 (100 %) 
day 5 25/25 X 24/25 = 24/25 (96%) 
day 7 25/25 X 24/25 X 23/24 = 23/25 (92%) 
day 9 25/25 X 24/25 X 23/24 X 23/23 = 23/25 (92%) 
day 11 25/25 X 24/25 X 23/24 X 23/23 X 21/22 = 21/25 (84%) 
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The probability of response is plotted stepwise on a 
graph against time. 
The Kaplan-Meier median is defined as the first day (n) 
where p(n) ~ 0.5. 
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